,PageNo,Text
0,page_0,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 1 of 88 CLINICAL TRIAL PROTOCOL PROTOCOL NUMBER: RD.06.SPR. 118295 CONFIDENTIAL This document contains confidential, proprietary information All the information provided to the Investigator and his/her staff and all data obtained through this GALDERMA clinical trial protocol are confidential. The Sponsor reserves all proprietary rights. No information may be disclosed to any third party without prior written consent from GALDERMA. NCT03915860"
1,page_1,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 7,7/(3$*( 7LWOH $0XOWL&HQWHU6WXG\WRHYDOXDWH6XEMHFW5HSRUWHG2XWFRPHVZLWK XVHRI7ULIDURWHQHJJFUHDPLQWKH WUHDWPHQWRIPRGHUDWHIDFLDODQGWUXQFDODFQHYXOJDULV 3URMHFW1DPHRU&'QXPEHU  3URM HFW1XPEHU  &OLQLFDO7ULDO3KDVH  &'   ,,,E ,1'1XPEHU  6321625  1DPH  *$/'(50$5(6($5&+ '(9(/230(17//& $GGUHVV  1RUWK)UHHZD\ )RUW:RUWK7; 7HOHSKRQH    )RUDQ\VDIHW\TXHVWLRQVSOHDVHFRQWDFWWKH&OLQLFDO6DIHW\2I ILFHU &62 XVLQJWKHFRQWDFW GHWDLOVSURYLGHGLQ6HFWLRQ  )RUDQ\PHGLFDOTXHVWLRQVUHODWHGWRWKHFOLQLFDOWULDOSURWRFR OSOHDVHFRQWDFWWKH0HGLFDO([SHUW XVLQJWKHFRQWDFWGHWDLOVEHORZ  1DPHDQG7LWOH  0'0HGLFDO([SHUW $GGUHVV  *DOGHUPD5 '//& 1RUWK)UHHZD\)RUW:RUWK7;86$ 7HOHSKRQH PRELOH  )D[  (PDLO PPD PPD PPD PPD"
2,page_2,GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 3 of 88 This clinical trial will be performed in compliance with applicable regulatory requirements and Good Clinical Practice (GCP). This clinical trial protocol follows guidelines outlined by the International Conference on Harmonisation (ICH) and the Galderma template.
3,page_3,GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 4 of 88 Table of Contents TITLE PAGE ............................................................................................................................................... 2 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ........................................................ 16 1 BACKGROUND AND RATIONALE ........................................................................................... 18 1.1 Medical background and short rationale for the clinical trial ............................................... 18 1.2 Drug profile ................................................................................................................................ 19 1.3 Risk/benefit assessm ent ............................................................................................................. 19 2 CLINICAL TRIAL OBJECTIVES AND CLINICAL HYPOTHESIS ..................................... 20 2.1 Clinical trial objectives .............................................................................................................. 20 2.2 Clinical hypotheses ..................................................................................................................... 20 3 OVERALL CLINICAL TRIAL DESCRIPTION ........................................................................ 21 3.1 Efficacy assessment .................................................................................................................... 21 3.2 Safety Assessment ...................................................................................................................... 21 3.3 Applicat ion areas........................................................................................................................ 21 4 CLINICAL TRIAL DURATION AND TERMINATION .......................................................... 23 5 SELECTION AND DISPOSITION OF CLINICAL TRIAL POPULATION .......................... 23 5.1 Number of subjects .................................................................................................................... 23 5.2 Clinic al trial population characteristics ................................................................................... 23 5.3 Inclusion criteria ........................................................................................................................ 23 5.4 Exclusion criteria ....................................................................................................................... 25 5.5 Previous and concomitant therapies......................................................................................... 28 5.5.1 Definition ............................................................................................................................... 28 5.5.2 Categories .............................................................................................................................. 28 5.5.3 Recording ............................................................................................................................... 28 5.5.4 Authorized concomitant therapies ...................................................................................... 29 5.5.5 Prohibited concomitant therapies ........................................................................................ 29 5.6 Procedures/reasons for subject discontinuation ...................................................................... 30 6 CLINICAL SUPPLIES ................................................................................................................... 32 6.1 Cli nical supply identification and use ...................................................................................... 32
4,page_4,GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 5 of 88 6.1.1 Study drug description ......................................................................................................... 32 6.1.2 Subject identification number ............................................................................................. 33 6.1.3 Kit number ............................................................................................................................ 33 6.1.4 Instructions for use and application .................................................................................... 33 6.1.5 Other supplies ........................................................................................................................ 34 6.2 Study drug packaging and labeling .......................................................................................... 35 6.3 Supplies management ................................................................................................................ 35 6.3.1 Accountability ....................................................................................................................... 35 6.3.2 Storag e of clinical study drug .............................................................................................. 35 6.3.3 Dispensing and return .......................................................................................................... 36 6.3.4 Treatment compliance management and record ............................................................... 36 6.4 Dose modification ....................................................................................................................... 37 7 CLINICAL TRIAL ASSESSMENT .............................................................................................. 37 7.1 Efficacy assessments .................................................................................................................. 37 7.1.1 Efficacy measurements ......................................................................................................... 37 7.1.2 Efficacy endpoints ................................................................................................................. 40 7.2 Safety assessment ....................................................................................................................... 41 7.2.1 Local tolerability assessment (of face and of trunk) .......................................................... 41 7.2.2 Adverse events ....................................................................................................................... 42 7.3 Other assessments ...................................................................................................................... 51 7.3.1 Photographs ........................................................................................................................... 51 7.3.2 Dermatology Life Quality Index (DLQI) / Children’s Dermatology Life Quality Index (C -DLQI) ....................................................................................................... 52 7.3.3 CompAQ for Facial and Truncal Acne ............................................................................... 53 7.3.4 EuroQoL 5 -Dimension (EQ -5D- 5L) .................................................................................... 54 7.3.5 Subject satisfaction questionnaire ....................................................................................... 54 7.3.6 Study drug acceptability questionnaire .............................................................................. 54 8 CLINICAL TRIAL VISITS DESCRIPTIONS AND PROCEDURES ...................................... 54 8.1 Description of clinical trial visits .............................................................................................. 54
5,page_5,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6FUHHQLQJYLVLW   6FUHHQLQJ%DVHOLQHYLVLW    8QVFKHGXOHGYLVLWV   6XEMHFWLQVWUXFWLRQV RWKHUWK DQVWXG\GUXJDGPLQLVWUDWLRQ    67$7,67,&$/0(7+ 2'63/$11('   6WDWLVWLFDODQDO\VLVSODQ   'DWDWUDQVIRUPDWLRQV   3RSXODWLRQVDQDO\]HGHYDOXDELOLW\DQGOLPLWDWLRQHYDOXDWLRQ RIELDV  'DWDSUHVHQWDWLRQDQGJUDSKLFV   6DPSOHVL]HGHWHUPLQDWLRQ   75$,1,1*021,725,1*'$7$0$1$*(0(1748$/,7<$6685$1&(  3HUVRQQHOWUDLQLQJ    &OLQLFDOPRQLWRULQJ   'DWDPDQDJHPHQW   4XDOLW\DVVXUDQFHDXGLWLQVSHFWLRQ   &KDQJHVLQFOLQLFDOWULDOFRQGXFWDPHQGPHQWV   &OLQLFDOWULDOFRQGXFW   $PHQGPHQWV   $WWULWLRQ    (7+,&6$1'*(1(5$/&/,1,&$/7 5,$/&21'8&7&216,'(5$7,216  ,QVWLWXWLRQDO5HYLHZ%RDUGRU,QGHSHQGHQW(WKLFV&RPPLWWHH   (WKLFDOFRQGXFWRIWKHFOLQLFDOWULDO   6XEMHFWLQIRUPDWLRQDQGFRQVHQW  CCI CCI"
6,page_6,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI &RQWUDFWXDOUHTXLUHPHQWV   'DWDFROOHFWLRQDQGDUFKLYLQJ   'DWDFROOHFWLRQ   6RXUFHGRFXPHQWDWLRQ    $UFKLYHV    ,QVXUDQFH    /,7(5$785(5()(5 (1&(/,67   $33(1', &(6    6XEMHFW6DWLVIDFWLRQ4XHVWLRQQDLUH   6WXG\'UXJ$FFHSWDELOLW\4XHVWLRQQDLUH   'HUPDWRORJ\/LIH4XDOLW\,QGH[ '/4,     &KLOGUHQ¶V'HUPDWRORJ\/LIH4XDOLW\,QGH[ &'/4,    42/4XHVWLRQQDLUHIRU)DFHDQG7UXQN$FQH \HDUVRIDJHDQG ROGHU   (XUR4R/'LPHQVLRQ (4'/    )LW]SDWULFN6NLQ& ODVVLILFDWLRQ   $FQH+DUPRQL]DWLRQ/HVLRQ&RXQW   $WURSKLF$FQH6FDU&RXQWV   3URWRFRO6LJQDWXUH3DJH   CCI"
7,page_7,GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 8 of 88 List of Tables Table 1 Clinical trial schematic ........................................................................................................... 13 Table 2 Schedule of assessments ......................................................................................................... 14 Table 3 Exit Form reasons for discontinuation .................................................................................... 31 Table 4 Description and usage of the study drug ................................................................................. 32 Table 5 Suspected sensitization - reaction grading .............................................................................. 49 Table 6 Suspected sensitization - conclusion ....................................................................................... 49
8,page_8,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJH RI 6<1236,6 &OLQLFDO7ULDO7LWOH  $0XOWL&HQWHU6WXG\WR(YDOXDWH6XEMHFW5HSRUWHG2XWFRPHVZLWK XVHRI7ULIDURWHQHJJ &UHDPLQWKH7UHDWPHQWRI0RGHUDWH)DFLDODQG7UXQFDO$FQH9XOJ DULV 6KRUW7LWOH  6XEMHFW5HSRUWHG2XWFRPHVZLWKXVHRI7ULIDURWHQHJJ&UHDP LQ6XEMHFWVZLWK0RGHUDWH)DFLDO DQG7UXQFDO$FQH9XOJDULV  /D\7LWOH 6WXG\LQJWKH(IIHFWVRIJJ &UHDPRQ6XEMHFWVZKRKDYH$FQH  &OLQLFDO7ULDOSKDVH  ,,,E &OLQLFDO7ULDO3RSXODWLRQ  6XEMHFWVZLWKPRGHUDWHDFQHYXOJDULVZLWKIDFLDODQGWUXQFDODF QHLQYROYHPHQW &OLQLFDO7ULDOREMHFWLYHV  7KHSXUSRVHRIWKLVVWXG\LVWRHYDOXDWHVXEMHFWUHSRUWHGRXWFR PHVZLWK7ULIDURWHQH FUHDP &OLQLFDO7ULDOGHVLJQ  0XOWLFHQWHURSHQODEHOVLQJOH DUPVWXG\RI7ULIDURWHQHFUHDP DSSOLHGRQFHGDLO\LQ WKHHYHQLQJIRUZHHNV 7RWDOQXPEHURIVXEMHFWV 3ODQQHG $SSUR[LPDWHO\VXEMHFWVZLOOEHHQUROOHGLQRUGHUWRREWDLQ VXEMHFWVDW FRPSOHWLRQ 1XPEHURIFOLQLFDOWULDO FHQWHUV 3ODQQHG  5HJLRQ V FRXQWU\ LHV LQYROYHG 3ODQQHG 8QLWHG6WDWHV &OLQLFDOWULDOGXUDWLRQ  'XUDWLRQRIVXEMHFW SDUWLFLSDWLRQ &OLQLFDOWULDOSDUWLFLSDWLRQIRUHDFKVXEMHFWLVDSSUR[LPDWHO\ ZHHNVRIVWXG\ WUHDWPHQWGD\V 1RWH 6XEMHFWVXSRQVWXG\FRPSOHWLRQHDUO\WHUPLQDWLRQZLOOU HWXUQWRVWDQGDUGRI FDUHZLWKWKHLUSK\VLFLDQ .H\LQFOXVLRQFULWHULD0DOHRUIHPDOH \HDUVRIDJHDQGROGHUDWWKH6FUHHQLQJYLVL W 7KH6XEMHFWKDVDIDFLDODFQH  .H\H[FOXVLRQFULWHULD7KHVXEMHFWKDVVHYHUHIRUPVRIDFQH HJDFQHFRQJOREDWDDF QH IXOPLQDQV RUVHFRQGDU\DFQHIRUP  HJFKORUDFQHGUXJLQGXFHG DFQHHWF CCI CCI CCI CCI"
9,page_9,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6<1236,6 &OLQLFDO7ULDO7LWOH  $0XOWL&HQWHU6WXG\WR(YDOXDWH6XEMHFW5HSRUWHG2XWFRPHVZLWK XVHRI7ULIDURWHQHJJ &UHDPLQWKH7UHDWPHQWRI0RGHUDWH)DFLDODQG7UXQFDO$FQH9XOJ DULV 7KHVXEMHFWKDVDQ\XQFRQWUROOHGRUVHULRXVGLVHDVHRUDQ\PHGL FDORU VXUJLFDOFRQGLWLRQWKDWPD\HLWKHULQWHUIHUHZLWKWKHLQWHUSUHW DWLRQRIWKHWULDO UHVXOWVDQGRUSXWWKHVXEMHFWDWVLJQLILFDQWULVN DFFRUGLQJW RWKH ,QYHVWLJDWRU¶VMXGJPHQW LIWKHVXEMHFWWDNHVSDUWWRWKHWULDO  7KHVXEMHFWKDVNQRZQRUVXVSHFWHGDOOHUJLHVRUVHQVLWLYLWLHVW RDQ\ FRPSRQHQWVRIDQ\RIWKHVWXG\GUXJV VHH,QYHVWLJDWRU¶V%URFKX UH  ,QYHVWLJDWLRQDOSURGXFW  /RFDWLRQRIWUHDWHGDUHD  )DFH &KLQOHIWFKHHNULJKWFKHHNQRVHDQGIRUHKHDG 7UXQFDOUHJLRQ ULJKWDQGOHIWXSSHUEDFNULJKWDQGOHIWVKRX OGHUVDQGULJKWDQGOHIW XSSHUDQWHULRUFKHVW  (IILFDF\$VVHVVPHQWV  (IILFDF\HQGSRLQWV 6XFFHVV5DWHGHILQHGDVWKHSHUFHQWDJHRIVXEMHFWVZKRDFKLHYH DQ,*$VFRUH RI $OPRVW&OHDU RU &OHDU $1'DWOHDVWDJUDGHLPSURYH PHQWIURP %DVHOLQHWR:HHNDQG:HHN 6XFFHVV5DWHGHILQHGDVWKHSHUFHQWDJHRIVXEMHFWVZKRDFKLHYH D3*$VFRUHRI  $OPRVW&OHDU RU &OHDU $ 1'DWOHDVWDJUDGHLPSURYHPHQ WIURP%DVHOLQH WR:HHNDQG:HHN 3HUFHQWFKDQJHLQIDFLDOQRQ±LQIODPPDWRU\OHVLRQFRXQWVIURP%D VHOLQHWRZHHN DQGZHHNCCI CCI CCI CCI CCI"
10,page_10,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6<1236,6 &OLQLFDO7ULDO7LWOH  $0XOWL&HQWHU6WXG\WR(YDOXDWH6XEMHFW5HSRUWHG2XWFRPHVZLWK XVHRI7ULIDURWHQHJJ &UHDPLQWKH7UHDWPHQWRI0RGHUDWH)DFLDODQG7UXQFDO$FQH9XOJ DULV 3HUFHQWFKDQJHLQIDFLDOLQIODPPDWRU\OHVLRQFRXQWVIURP%DVHOL QHWRZHHNDQG ZHHN 3HUFHQWFKDQJHLQWUXQFDOQRQLQIODPPDWRU\OHVLRQFRXQWVIURP% DVHOLQHWRZHHN DQGZHHN 3HUFHQWFKDQJHLQWUXQFDOLQIODPPDWRU\OHVLRQFRXQWVIURP%DVHO LQHWRZHHN DQG:HHN 6XEMHFW¶VDVVHVVPHQWRIIDFLDODFQHLPSURYHPHQW 6DIHW\DVVHVVPHQW  6DIHW\DVVHVVPHQWVZLOOEHFRQGXFWHGIRUDOOVXEMHFWVDW6FUHHQ LQJEDVHOLQHDQGDOO VXEVHTXHQWYLVLWVXQWLOWKH:HHN9LVLW7KHVDIHW\SDUDPHWHU VDUH$GYHUVH(YHQWV ORFDOWROHUDELOLW\DVVHVVPHQWV 0HDVXUHPHQWFULWHULD 6XEMHFWUHSRUWHGRXWFRPHV 4XDOLW\2I/LIHTXHVWLRQQDLUHV  x'HUPDWRORJ\ /LIH ,QGH[ TXHVWLRQQLDUH '/4,  TXHVWLRQQDLUHV FRPSDULQJ %DVHOLQHWR:HHNVDQGRU(DUO\WHUPLQDWLRQ x&RPS$4 IRU!\HDUVDJH FRPSDULQJ%DVHOLQHWR:HHNVDQG RU (DUO\WHUPLQDWLRQ x(4'/FRPSDULQJ%DVHOLQHWR:HHNVDQGRU(DUO\WHUPLQD WLRQ x6XEMHFWVDWLVIDFWLRQTXHVWLRQQDLUH DW:HHN(DUO\WHUPLQDWLRQ (IILFDF\ x,QYHVWLJDWRU¶V*OREDO$VVHVVPHQW ,*$ DFQHVHYHULW\RIWKHIDFHRQDVFDOH IURP &OHDU WR 6HYHUH DWHDFKYLVLW7RWDOOHVLRQQRQL QIODPPDWRU\ OHVLRQ RSHQ DQG FORVHG FRPHGRQHV  LQIODPPDWRU\ OHVLRQ SDSXOH V SXVWXOHV RQWKHIDFH LQFOXGLQJWKHQRVH DWHDFKYLVLW x3K\VLFLDQ*OREDO$VVHVVPHQW 3*$ DFQHVHYHULW\RIWKHWUXQNRQDVFDOH IURP &OHDU WR 6HYHUH DWHDFKYLVLW7RWDOOHVLRQQRQL QIODPPDWRU\ OHVLRQ RSHQ DQG FORVHG FRPHGRQHV  LQIODPPDWRU\ OHVLRQ SDSXOH V SXVWXOHV RQWUXQNDWHDFKYLVLW 6DIHW\ x/RFDO WROHUDELOLW\ SDUDPHWHUV  HU\WKHPD VFDOLQJ GU\QHVV DQG VWLQJLQJEXUQLQJ ZLOOEHHYDOXDWHGDWHDFKYLVLWRQD SRLQWVFDOHUDQJLQJ IURP QRQH WR VHYHUH   x$GYHUVH(YHQWV ZKLFKLQFOXGHV$(V6$($(6,DQG'HDWK 2WKHUCCI CCI CCI"
11,page_11,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6<1236,6 &OLQLFDO7ULDO7LWOH  $0XOWL&HQWHU6WXG\WR(YDOXDWH6XEMHFW5HSRUWHG2XWFRPHVZLWK XVHRI7ULIDURWHQHJJ &UHDPLQWKH7UHDWPHQWRI0RGHUDWH)DFLDODQG7UXQFDO$FQH9XOJ DULV $QDO\VHGYDULDEOHV 6XEMHFWUHSRUWHGRXWFRPHV x'/4,F'/4,DQG&RPS$4DW%DVHOLQHDQG:HHN(DUO\WHUPLQD WLRQ x6XEMHFWVDWLVIDFWLRQTXHVWLRQQDLUHVDW:HHN(DUO\WHUPLQ DWLRQ x(4'/DWEDVHOLQHDQG:HHN(DUO\WHUPLQDWLRQ (IILFDF\YDULDEOH x 3HUFHQWFKDQJHLQWKHIDFLDO,/1, OHVLRQFRXQWIURP %DVHOLQHWR:HHNVDQG x 3HUFHQWFKDQJHLQWKHWUXQN,/1, OHVLRQFRXQWIURP %DVHOLQHWR:HHNVDQG x6XFFHVVUDWHRI,*$DVWKHSHUFHQWDJHRIVXEMHFWVZKRDFKLHYHG DQ,*$ ZLWKDVFRUHRI DOPRVWFOHDU RU &OHDU $1'DQDWOHDVWD JUDGH LPSURYHPHQWIURP%DVHOLQHDWHDFKVWXG\YLVLW x6XFFHVVUDWHRI3*$DVWKHSHUFHQWDJHRIVXEMHFWVZKRDFKLHYHG D3*$ ZLWKDVFRUHRI DOPRVWFOHDU RU &OHDU $1'DQDWOHDVWD JUDGH LPSURYHPHQWIURP%DVHOLQHDWHDFKVWXG\YLVLW 6DIHW\Y DULDEOHV  x/RFDOWROHUDELOLW\SDUDPHWHUVZLOOEHDVVHVVHGDW%DVHOLQHDQG HDFKSRVW EDVHOLQH YLVLWV RQ DOO WUHDWHG DUHDV   x/RFDOWROHUDQFH 5DZYDOXHDWHDFKYLVLWDQGZRUVW VFRUHDFURVVYLVWRI 6XEMHFWVDFURVVVFRUHVDWHDFKSRVWEDVHOLQHYLVLW x,QFLGHQFHRIDGYHUVHHYHQWV $(6,6$(V'HDWKOHDGLQJWRGLVF RQWLQXDWLRQ RUHDUO\WHUPLQDWLRQ 2WKHU 3ULQFLSDOVWDWLVWLFDOPHWKRG  7KH,QWHQWWR7UHDW ,77 SRSXODWLRQFRQVLVWVRIDOOHQUROOHGV XEMHFWV7KH6DIHW\ SRSXODWLRQ 6$) FRQVLVWVRIWKH,77SRSXODWLRQZKRDSSOLHGDW OHDVWRQHGRVHRI WUHDWPHQW 7KHPDLQREMHFWLYHRIWKLVVWXG\LVWRHYDOXDWHWKHVXEMHFWUHS RUWHGRXWFRPHVZLWK WULIDURWHQHZLWKDQGXSWRZHHNVRIWUHDWPHQW $OOYDULDEOHVZLOOEHGHVFULSWLYHO\VXPPDUL]HG$OOVDIHW\HQGS RLQWVZLOOEHVXPDUL]HG EDVHGRQ6$)SRSXODWLRQDQG4XDOLW\RIOLIHDQG(IILFDF\HQGSRL QWVZLOOEHVXPDUL]HGCCICCI CCICCI CCI CCI CCI CCI"
12,page_12,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6<1236,6 &OLQLFDO7ULDO7LWOH  $0XOWL&HQWHU6WXG\WR(YDOXDWH6XEMHFW5HSRUWHG2XWFRPHVZLWK XVHRI7ULIDURWHQHJJ &UHDPLQWKH7UHDWPHQWRI0RGHUDWH)DFLDODQG7UXQFDO$FQH9XOJ DULV XVLQJ,77SRSXODWLRQ7KHODVWREVHUYDWLRQFDUULHGIRUZDUG /2& ) PHWKRGZLOOEHXVHG WRLPSXWHPLVVLQJHIILFDF\YDOXHVZKHUHDSSOLFDEOH 7KHUHLVQRIRUPDOK\SRWKHVLVWREHWHVWHG$QHVWLPDWLRQDSSUR DFKZLOOEHSHUIRUPHG 3RLQWHVWLPDWHDQG FRQILGHQFHLQWHUYDOZLOOEHFRQVWUXFWHG ZKHUHSRVVLEOH $SSUR[LPDWHO\VXEMHFWVZLOOEHHQUROOHGWRHYDOXDWHWKHVXEM HFWUHSRUWHGRXWFRPHV TXDOLW\RIOLIHDQGVDWLVIDFWLRQVXUYH\ 7KHVDPSOHVL]HLVQ RWEDVHGRQDQ\IRUPDO K\SRWKHVLVWHVWLQJ 7DEOH &OLQLFDOWULDOVFKHPDWLF CCI"
13,page_13,*$/'(50$5 ' 5'635 3URWRFRO9-XQ 3DJHRI 7DEOH 6FKHGXOHRIDVVHVVPHQWV CCI
14,page_14,*$/'(50$5 ' 5'635 3URWRFRO9-XQ 3DJHRI CCI
15,page_15,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 16 of 88 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS Abbreviation Term °C Degrees Celsius °F Degrees Fahrenheit AE Adverse Event AESI Adverse Event of Special Interest CDLQI Children’s Dermatology Life Quality Index CDMS Clinical Data Management System CRA Clinical Research Associate CRF Case Report Form CRO Contract Research Organization CSO Clinical Safety Officer CSR DLQI Clinical Study Report Dermatology Life Quality Index DMP Data Management Plan EDC Electronic Data Capture e.g. For Example (Latin: exempli gratia) ET Early Termination etc. Et cetera FDA Food and Drug Administration FSI First Subject In (first subject screened, i.e. who signs the Informed Consent Form) GCP Good Clinical Practice HIPAA Health Insurance Portability and Accountability Act of 1996 IB Investigator’s Brochure ICF ICH Informed Consent Form International Conference on Harmonization i.e. That is (Latin: id est) IEC Independent Ethics Committee IGA Investigator’s Global Assessment IND Investigational New Drug IRB Institutional Review Board ITT Intention -to-treat ITTT Intent -to-treat on the Trunk IUD Intrauterine Device LOAEL Lowest -observed -adverse -effect level"
16,page_16,GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 17 of 88 Abbreviation Term LOCF Last Observation Carried Forward LSI Last Subject In (Last subject enrolled/randomized) LSO Last Subject Out (Last subject who completed his/her last clinical trial visit) MI Multiple Imputation MD Medical Doctor MedDRA Medical Dictionary for Regulatory Activities mL Milliliter NOAEL no observed adverse effect level OTC Over -the-Counter PGA Physician Global Assessment PK Pharmacokinetics PP Per-Protocol PT Preferred term RAR Retinoic Acid Receptor RXR Retinoic X Receptor SAE Serious Adverse Event SAP Statistical Analysis Plan SAF Safety SAFT Safety Population on the Trunk SIN Subject Identification Number SOC System Organ Class SOP Standard Operating Procedure SPF Sun Protection Factor TEAE Treatment -Emergent Adverse Event UPT Urine Pregnancy Test USA United States of America UV Ultraviolet
17,page_17,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 18 of 88 1 BACKGRO UND AND RATIONALE 1.1 Medical background and short rationale for the clinical trial Acne is one of the most common skin disorders treated by dermatologists. While acne is highly prevalent in youth with around 85% of teenagers affected at some point in time.1 In European populations over 70 –80 % of all males will experience acne in some point of their lifetime. In the USA, acne has been reported to affect an estimated number of over 25 (17–45) million Americans.2 As acne is a chronic and relapsing disease, normalizing follicular desquamation is then the key to achieve and maintain control of acne. It can persist for years and result in disfigurement and permanent scarring, and may have serious adverse effects on psychosocial development, resulting in emotional problems, withdrawal from society, and depression. 3 Teenagers with even mild acne feel stigmatized and frustrated.4 Today it is establi shed that retinoids acts in the pathology of acne vulgaris: it is a potent modulator of cellular differentiation and keratinisation. Topical retinoids have been the first- line treatment for most forms of acne vulgaris. 5 Acne is a multifactorial inflammatory disease affecting pilosebaceous follicles .6, 7, 2 Both clinically and pathophysiologically, truncal acne and facial acne are similar in terms of specific lesions ( eg, closed comedones, open comedones, papules and pustules etc.). Further, the management of truncal acne vulgaris warrants an approach similar to what is used for the treatment of facial acne 8. Truncal acne has been estimated to occur in over half the number of acne patients even if facial acne is the most common and often the most visible form of acne. In one study of patients referred to a dermatology clinic, it was found more than 60 percent of individuals had back acne 9. In another cohort of 696 patients, half of patients with facial acne were found to have coexistent truncal involvement. Approximately 50% of patients who presented with acne vulgaris demonstrated involvement on the chest and/or back, with more than 3% presenting with truncal acne lesions alone. Interestingly, approximately 1 out of 4 patients who presented with both f acial and truncal acne involvement did not voluntarily mention the presence of truncal acne as part of their presenting complaint. In such cases, the presence of truncal acne lesions was detected by clinical examination. The majority of patients presenting with truncal acne vulgaris exhibited mild to moderate severity and more than 75% were interested in treatment for truncal acne lesions. 10 Trifarot ene, a new gen eration topical retinoid with its unique mechanism of action, binds to specific retinoic acid receptor (RAR -ɤ).11 Current evidence suggests that topical Trifarotene normalizes the differentiation of follicular epithelial cells resulting in decreased microcomedone formation. It may be an ideal topical age nt with high selectivity towards gamma receptors, skin metabolism and with very low systemic absorption for management of acne treatment. Currently under clinical development with studies in acne vulgaris of face and trunk. However, it is also important in terms of patient -reported outcomes (PRO) to assess satisfaction that might be caused by the treatment or by acne itself and to also assess the local tolerability. Proper skin care is considered to be an important component of the total management plan for patients with acne vulgaris. There are several ways to mitigate adverse effect and prevent further worsening of skin tolerability. These include initiating patients on lower concentrations of topical retinoids, choosing cream or lotion (rather than gel). Trifarotene, being a highly selective RAR -ɤ"
18,page_18,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJH RI ZLWKORZFRQFHQWUDWLRQDQGLQF UHDPIRUPXODWLRQZLWKDGHTXDWHU HFRPPHQGDWLRQVIRULWVXVH ZRXOGEHDSSURSULDWHLQDFQHV XEMHFWV6NLQLUULWDWLRQFDQOHDG WRSRRUFRPSOLDQFHDQGVXEVHTXHQWO\ ODFNRIHIILFDF\7KHUHIRUHDGDSWHGWUHDWPHQWLQVWUXFWLRQVIRU XVHHVSHFLDOO\GXULQJWKHILUVWZHHNV RIWUHDWPHQWPD\UHVXOWLQDEHWWHUWROHUDELOLW\OHDGLQJWRLP SURYHGFRPSOLDQFHHIILFDF\DQG SDWLHQWVDWLVIDFWLRQ+HQFHWKH DGGLWLRQRIDWRSLFDOJHQWOHP RLVWXUL]HUIRUWKHVHVXEMHFWVDQG UHFRPPHQGDWLRQIRUDYRLGLQJVXQH[SRVXUHLVDSDUWRIWKHVNLQ FDUHUHJLPHQIRUWKHVHDFQH VXEMHFWV0LQLPL]LQJVNLQLUULWDWLRQDQGSKRWRSURWHFWLRQFDQEHDFKLHYHG E\WKHXVHRIQRQ FRPHGRJHQLFPRLVWXUL]HUVZLWKD SSURSULDWHVXQSURWHFWLRQIDFWRU  63) RIRUKLJKHUFDQK\GUDWH DQGSURWHFWWKHVNLQI URP89LUUDGLDWLRQ $FQHFDQSHUVLVWIRU\HDUVDQGPD\VHULRXVO\DIIHFWWKHSV\FKRV RFLDOGHYHORSPHQWUHVXOWLQJLQ HPRWLRQDOSUREOHPVZLWKGUDZDOIURPVRFLHW\DQGGHSUHVVLRQ,IQRWWUHDWHGDFQHPD\FDXVH VHULRXVSK\VLFDODQGHPRWLRQDOVFDUULQJDQGFDQVLJQLILFDQWO\L PSDFWWKHTXDOLW\RIOLIHRIWKRVH DIIHFWHGE\WKHGLVHDVH7KHUHIRUHWKLVVWXG\DLPVWRHYDOXDWHDFQHVXEMHFW¶VVDWLVIDFW LRQDQG TXDOLW\RIOLIHZLWK7ULIDURWHQHPHGLFDWLRQDVLWLVNQRZQIRU WRSLFDOUHWLQRLGVWREHVHQVLWLYHRQ VNLQ7KHORFDOWROHUDQFHRIWKHWUHDWPHQWLQWHUPVRIHU\WKHPD VFDOLQJGU\QHVVVWLQJLQJEXUQLQJ ZLOODOVREHHYDOXDWHG 7KLVFOLQLFDOWULDOLVGHVLJQHGWRHYDOXDWHWKH352ZLWKXVHRI 7ULIDURWHQHLQVXEMHFWVZLWKPRGHUDWH IDFLDODQGWUXQFDODFQHYXOJDULVDQGDOVRWRDVVHVVWKHLPSDFW RIVXFKWUHDWPHQW LQVWUXFWLRQVRQ RYHUDOOHIILFDF\VXEMHFWVDWLVIDFWLRQDQGVDIHW\ZLWKPDQDJH PHQWRIVNLQLUULWDWLRQZKLFKZDVQRW VSHFLILFDOO\HYDOXDWHGGXULQJWKHFOLQLFDOGHYHORSPHQW 'UXJSURILOH 5HWLQRLGV SOD\ D FHQWUDO SDUW LQ WKHWUHDWPHQW RIDFQHGXHWRW KHLU NHUDWRO\WLFDFWLYLW\ DQG PRGXODWLRQRISUROLIHUDWLRQDQG GLIIHUHQWLDWLRQRINHUDWLQRF\WH VOHDGLQJWRWKHHOLPLQDWLRQRIWKH FRPHGRQH 5HWLQRLGV H[HUW WKHLU HIIHFWV RQ D PROHFXODU OHYHO WKURXJK QXFO HDU UHFHSWRUV  5HWLQRLF $FLG 5HFHSWRU 5$5 DQG5H WLQRLF;5HFHSWRU 5;5 ZKLFKHDFKKDYHW KUHHVXEW\SHV DEDQGJ 7ULIDURWHQHGHYHORSHGE\*$/'(50 $5 'IRUWRSLFDODGPLQLVWUDWL RQVKRZVVHOHFWLYHELQGLQJ WR5$5DQGQRWWR5;5    5LVNEHQHILWDVVHVVPHQW 7KHPRVWVHULRXVULVNDVVRFLDWHGZLWKUHWLQRLGVLVUHODWHGWRW HUDWRJHQLFLW\DQGHPEU\RWR[LFLW\ 6\VWHPLFH[SRVXUHWR7ULIDURWHQHOLNHDOOUHWLQRLGVPD\FDXVH IHWDOKDUPIROORZLQJV\VWHPLF H[SRVXUHLQSUHJQDQWZRPHQCCI"
19,page_19,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 7DNHQ WKH GRFXPHQWHG HIIHFWLYHQH VV RI 7ULIDURWHQHFUHDP JJ L Q W K H W U H D W P H Q W R I D F Q H   WKHULVNEHQHILWDVVHVVPHQW LVVXSSRUWLYHRIWKHVWXG\ &/,1,&$/75,$/2%-(&7,9( 6$1'&/,1,&$/+<327+(6,6 &OLQLFDOWULDOREMHFWLYHV 7KHSXUSRVHRIWKLVVWXG\LVW RHYDOXDWHVXEMHFWUHSRUWHGRXWFR PHVZLWK7ULIDURWHQHFUHDP &OLQLFDOK\SRWKHVHVCCI CCI"
20,page_20,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 29(5$//&/,1,&$/75,$/'(6&5,37,21 0XOWLFHQWHUVWXG\IRU7ULIDURWHQHFUHDPDSSOLHGRQFHGDLO\IRU ZHHNVLQWKHHYHQLQJ 7ULIDURWHQHJJFU HDPDSSOLHGRQFHGDLO\ (IILFDF\DVVHVVPHQW 7KHHIILFDF\HQGSRLQWFRQVLVWV RIWKHIROORZLQJHQGSRLQWV  x6XFFHVV5DWHGHILQHGDVWKHSHUF HQWDJHRIVXEMHFWVZKRDFKLHYH DQ,*$VFRUHRI  $OPRVW&OHDU RU &OHDU $1' DWOHDVWDJUDGHLPSURYHPHQ WIURP%DVHOLQHWR :HHNDQG:HHN x6XFFHVV5DWHGHILQHGDVWKHSHUF HQWDJHRIVXEMHFWVZKRDFKLHYH D3*$VFRUHRI  $OPRVW&OHDU RU &OHDU $1' DWOHDVWDJUDGHLPSURYHPHQ WIURP%DVHOLQHWR :HHNDQG:HHN x3HUFHQWFKDQJHLQIDFLDOQRQ±L QIODPPDWRU\OHVLRQFRXQWVIURP%D VHOLQHWRZHHNDQG ZHHN x3HUFHQWFKDQJHLQIDFLDOLQIODPPDWRU\OHVLRQFRXQWVIURP%DVHOL QHWRZHHNDQGZHHN  x3HUFHQWFKDQJHLQWUXQFDOQRQLQIO DPPDWRU\OHVLRQFRXQWVIURP% DVHOLQHWRZHHNDQG ZHHN x3HUFHQWFKDQJHLQWUXQFDOLQIOD PPDWRU\OHVLRQFRXQWVIURP%DVHO LQHWRZHHNDQG :HHN 6DIHW\$VVHVVPHQW 6DIHW\ HYDOXDWLRQV ZLOO EH SHUIRUPHG DW %DVHOLQH DQG DW :HHNV      DQG (DUO\7HUPLQDWLRQ (7 8QVFK HGXOHGYLVLWV7KHVHHYDOXDWLRQV ZLOOFRQVLVWRIDVVHVVPHQWRI ORFDOWROHUDELOLW\DQGDGYHU VHHYHQWVDWHDFKYLVLWCCI CCI CCI"
21,page_21,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
22,page_22,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI &/,1,&$/75,$/'85$7 ,21$1'7(50,1$7,21 7KHSODQQHGFOLQLFDOWULDOGXUDWLRQ IURP)6,WR/62 LVDSSUR[ LPDWHO\ 7KHGDWHRIHQG RIWKHFOLQLFDOWULDOLVGHILQHGDVWKHGDWHRIWKHODVWYLVLW RIWKHODVWVXEMHFWZKRSDUWLFLSDWHVLQWKH WULDO 7KHSODQQHGGXUDWLRQRIU HFUXLWPHQW LH)URP)6,WR/6, LVD SSUR[LPDWHO\  3ULRUWRVXEMHFWHQUROPHQWDVFUHHQLQJSHULRGODVWLQJ DW WKHPD[LPXPLVDXWKRUL]HG &OLQLFDOWULDOSDUWLFLSDWLRQIRUHDFKVXEMHFWLVDSSUR[LPDWHO\   *$/'(50$PD\GHFLGHWRSUHPDWXUHO\WHUPLQDWHRUVXVSHQGWKHSDU WLFLSDWLRQRIDSDUWLFXODU FOLQLFDOWULDOFHQWHU HJIRU QRQLQFOXVLRQRUQRQFRPSOLDQF HZLWKSURWRFROUHJXODWLRQVRU*&3  RUSUHPDWXUHO\VXVSHQGWKHFOLQLFDOWULDO HJIRUVDIHW\VW XG\GUXJTXDOLW\UHJXODWRU\HIILFDF\ RUORJLVWLFDOUHDVRQV DWDQ\ WLPHZLWKDSSURSULDWHQRWLILFDWL RQ 6(/(&7,21$1'',6326,7,212) &/,1,&$/75,$/3238/$7,21 1XPEHURIVXEMHFWV &OLQLFDOWULDOSRSXODW LRQFKDUDFWHULVWLFV ,QRUGHUWREHHOLJLEOHIRUWKHWULDOVXEMHFWVPXVWIXOILOODO ORIWKHIROORZLQJFULWHULDDW%DVHOLQHYLVLW 6RPHFULWHULDDUHWREHFKHFNHGDWWKH6FUHHQLQJYLVLW6XEMHFW VPD\EHUHVFUHHQHGRQFHXQOHVVWKH UHDVRQIRUVFUHHQIDLOXUHLVUHOD WHGWRDFQHVHYHULW\ ,*$RU3 *$ RUOHVLRQFRXQWV ,QFOXVLRQFULWHULD  7KHVXEMHFWLVDPDOHRUIHPDOH  \HDUVRIDJHDQGROGHUDW 6FUHHQLQJYLVLW  6XEMHFWZLWKFOLQLFDOGLD JQRVLVRIDFQHYXOJDULVCCI CCI CCI CCI CCI CCI CCI"
23,page_23,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI D ,QYHVWLJDWRU¶V*OREDO$VVHVVPHQW ,*$ VFRUHRI 0RGHUDWH E 7UXQFDODFQHVHYHULW\JUDGHRI PRGHUDWH RQWKH3K\VLFLDQ *OREDODVVHVVPHQW 3*$ VFDOH  ,QJHQHUDOJRRGKHDOWK SK\VLFDO PHQWDODQGVRFLDOZHOOEHL QJQRWPHUHO\WKHDEVHQFHRI GLVHDVHLQILUPLW\ DFFRUG LQJWRVXEMHFWVHOIUHSRUW  +DYLQJ)LW]SDWULFNVNLQSKRWRW\S H,9, UHIHUWR)LW]SDWULFN 6NLQ&ODVVLILFDWLRQ   7KHVXEMHFWLVDIHPDOHRIQRQ FKLOGEHDULQJSRWHQWLDO SUHPH QDUFKHDORUSRVWPHQRSDXVDO >DEVHQFHRIPHQVWUXDOEOHHGLQJIRU\HDUSULRUWR6FUHHQLQJZ LWKRXWDQ\RWKHUPHGLFDO UHDVRQ@K\VWHUHFWRP\RUELODWHUDORRSKRUHFWRP\   7KHVXEMHFWLVDIHPDOHRIFKLOGEHDULQJSRWHQWLDO :LWKDQHJDWLYHXULQHSUHJQDQF\WH VW 837 DW6FUHHQLQJDQG%DV HOLQHYLVLWV :KRDUHZLOOLQJWRWDNH837VWKU RXJKRXWWKHFRXUVHRIWKHVWXG\  :KRKDVEHHQVWULFWO\DEVWLQHQWIRUPRQWKSULRUWR6FUHHQLQJ %DVHOLQHDQGDJUHHVWR FRQWLQXHIRUWKHGXUDWLRQRIW KHFOLQLFDOWULDODQGDWOHDVW PRQWKDIWHUWKHODVWVWXG\ GUXJDSSOLFDWLRQ 25 :KRDJUHHVWRXVHDQHIIHFWLYHDQGDSSURYHGFRQWUDFHSWLYHPHWKR G V IRUWKHGXUDWLRQ RIWKHVWXG\DQGDWOHDVWPRQWKDIWHUWKHODVWVWXG\GUXJDSS OLFDWLRQ$QHIIHFWLYH PHWKRGRIFRQWUDFHSWLRQLVGHILQHGDV  DELODWHUDOWXEDOOLJDWLRQ  EDSSURYHGFRPELQHGRUDO FRQWUDFHSWLYHV HVWURJHQVDQGSURJHVWHUR QH LPSODQWHGRU LQMHFWDEOHFRQWUDFHSWLYHVRUKRUPRQDOFRQWUDFHSWLYHYDJLQDOUL QJVZLWKDVWDEOH GRVHIRUDWOHDVWPRQWKSULRUW RWKH6FUHHQLQJ%DVHOLQHYLVLW  FKRUPRQDO LQWUD XWHULQH GHYLFH ,8'  LQVHUWHG DW OHDVW  PRQWK S ULRU WR WKH 6FUHHQLQJ%DVHOLQHYLVLW  GYDVHFWRPL]HGSDUWQHUIRUDWOHDV WPRQWKVSULRUWRWKH6FUHHQL QJ%DVHOLQHYLVLW  ,IDIHPDOHRIFKLOGEHDULQJ SRWHQWLDOXVHVFRPELQHGRUDOFRQW UDFHSWLYHVDSSURYHGDVDFQH WUHDWPHQWV HJ2UWKR7UL&\FOHQ<D]'LDQH WKHGRVHVKRXOGEHVWDEOHIRUDW OHDVWPRQWKVSULRUWRWKH 6FUHHQLQJ%DVHOLQHYLVLW  )RUDSUHPHQVWUXDOIHPDOHZ KREHJLQVPHQVHVGXULQJWKHVWXG\ CCI CCI"
24,page_24,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI $JUHHVWREHVWULFWO\DEVWLQHQW IRUWKHGXUDWL RQRIWKHFOLQLFD OWULDODQGDWOHDVWPRQWK DIWHUWKHODVWVWXG\GUXJDSSOLFDWLRQ 25 $JUHHVWRXVHDQHIIHFWLYHDQGDSSURYHGFRQWUDFHSWLYHPHWKRG V IRUWKHGXUDWLRQRI WKHVWXG\DQGDWOHDVWPRQWKDIWHUWKHODVWVWXG\GUXJDSSOLF DWLRQDQGDJUHHVWR XQGHUJRSUHJQDQF\WHVWV$QHIIH FWLYHPHWKRGRIFRQWUDFHSWLRQL VGHILQHGDVDSSURYHG FRPELQHGRUDOFRQWUDFHSWLYHV RHVWURJHQVDQGSURJHVWHURQH LPS ODQWHGRULQMHFWDEOH FRQWUDFHSWLYHVRUKRUPRQDOLQWU DXWHULQHGHYLFH ,8' RUKRUPR QDOFRQWUDFHSWLYH YDJLQDOULQJV  7KHVXEMHFWDJUHHVWRSDUWLFLS DWHLQWKHVWXG\YHULILHGE\ GDWLQJDQGVLJQLQJDQDSSURYHG ZULWWHQ,QIRUPHG&RQVHQW)RUP ,&) RUIRUVXEMHFWVXQGHUDJHR IPDMRULW\DQDVVHQWIRUP VLJQHGE\WKHVXEMHFW LIUHTXL UHG LQFRQMXQFWLRQZLWKDQ,&) VLJQHGE\WKHSDUHQW V OHJDO UHSUHVHQWDWLYHDWWKH6FUHHQLQJ YLVLWEHIRUHDQ\VWXG\SURFHGXU HV  $SSULVHGRI+,3$$ +HDOWK,QV XUDQFH3RUWDELOLW\DQG$FFRXQWD ELOLW\$FW DQGLVZLOOLQJWR VKDUHSHUVRQDOLQIRUPDWLRQDQGGDWD DVYHULILHGE\VLJQLQJDZ ULWWHQDXWKRUL]DWLRQDWWKH 6FUHHQLQJ%DVHOLQHYLVLW )RUVXEMHFWVXQGHUWKHDJHRI   +DYLQJDSDUHQWRUOHJDOJXD UGLDQZKRLV\HDUVRIDJHRU ROGHUDQGSUHVHQWVSURRIRI JXDUGLDQVKLS HJLQVXUDQFHFDU GFHUWLILFDWHRIUHVLGHQFHRU FRS\RIRIILFLDOO\LVVXHG IDPLO\UHJLVWUDWLRQ DWVFUHHQLQJEDVHOLQHYLVLW  ([FOXVLRQFULWHULD 6XEMHFWZLWKVHYHUHDFQH ,*$RU3*$!   7KHVXEMHFWVKDVVHYHUHIRUPVRIDFQH HJDFQHFRQJOREDWHD FQHIXOPLQDQV RUVHFRQGDU\ IRUP HJ&KORUDFQHGUXJLQGXFHGDFQHHWF CCI CCI CCI"
25,page_25,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI  7KHVXEMHFWKDVDQ\DFQHF\VWR QWKHIDFHDW6FUHHQLQJDQG%D VHOLQH  7KHVXEMHFWKDVDQ\DFQHF\VWV RQWKHWUXQNDW6FUHHQLQJDQG %DVHOLQH CCI
26,page_26,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
27,page_27,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 3UHYLRXVDQGFRQFRPLWDQWWKHUDSLHV 'HILQLWLRQ &RQFRPLWDQWWKHUDSLHVDUHGHILQHGDVIROORZV  DQ\H[LVWLQJWKHUDSLHVRQJRLQJDWWKHEDVHOLQHYLVLWRUVWDUWLQ JDIWHUWKHEDVHOLQHYLVLWRU DQ\FKDQJHVWRH[LVWLQJWKHUDSLHV VXFKDVFKDQJHVLQGRVHRUI RUPXODWLRQ GXULQJWKHFRXUVHRI WKHFOLQLFDOWULDORU DQ\QHZWKHUDSLHVUHFHLYHGE\ WKHVXEMHFWZLWKVWDUWRQRUDIWH UWKHEDVHOLQHYLVLW $Q\QHZFRQFRPLWDQWWKHUDS\RUPRGLILFDWLRQRIDQH[LVWLQJWKHU DS\PD\EHOLQNHGWRDQ DGYHUVHHYHQW $( $FRUUHVSRQGL QJ$GYHUVH(YHQW)RUPPXVWEH FRPSOHWHGWRDFFRXQWIRU WKHFKDQJHLQWKHUDS\H[FHSWLQ VRPHFDVHVVXFKDVWKHUDS\XVH GIRUSURSK\OD[LVGRVH PRGLILFDWLRQ GRQHGXULQJYLVLW RUE\FDOO IRU DFKURQLFFRQGL WLRQHWF &DWHJRULHV 7KHIROORZLQJWZRFDWHJRULHVDUH WREHFRQVLGHUHGIRUSUHYLRXV DQGFRQFRPLWDQW WKHUDSLHV  'UXJVWKHUDSLHV LQFOXGLQJ EXW QRW OLPLWHG WR SUHVFULSWLRQ RY HUWKHFRXQWHU 27&  ELUWK FRQWURO SLOOVSDWFKHVKRUPRQDO GHYLFHV YLWDPLQV PRLVWXUL]HUV  VXQVFUHHQV KHUEDO PHGLFLQHVVXSSOHPHQWVDQGKRP HRSDWKLFSUHSDUDWLRQV 0HGLFDODQGVXUJLFDOSURFHGXUHVLQFOXGLQJEXWQRWOLPLWHGWR ODVHUUDGLDWLRQSURFHGXUHV GHUPDOILOOHUV;UD\V H[FOXGLQJGHQWDO;UD\V HWF 5HFRUGLQJCCI CCI
28,page_28,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJH RI 3UHYLRXV DQG FRQFRPLWDQW WKHUDSLHV DUH WR EH UHFRUGHG RQ WKH 'U XJV7KHUDSLHV IRUP IRUGUXJVWKHUDSLHV DQGRURQWKH0HGLFDODQG6XUJLFDO3URFHG XUHVIRUP IRUPHGLFDOVXUJLFDO SURFHGXUHV LQWKHFDVHUHSRUWIRUP &5)  &RQFRPLWDQWWKHUDSLHV LQFOXGLQJSUHIHUUHGRUSURYLGHGPRLVWXUL ]HU DUHWREHUHFRUGHGUHYLHZHG DQGXSGDWHGDWHDFKYLVLW(YHU\ DWWHPSWVKRXOGEHPDGHWRNHHS FRQFRPLWDQWWKHUDS\GRVLQJDQG UHJLPHQFRQVWDQWGXULQJWKHWULDO $XWKRUL]HGFRQFRPLWDQWWKHUDSLHV 8QOHVVOLVWHGXQGHUWKHH[FOXVLRQFULWHULD 6HFWLRQ LWHP>@ RULQSURKLELWHGFRQFRPLWDQW WKHUDSLHVWKHIROORZLQJWKHUDSLHVDUHDOORZHGDVORQJDVWKH\ DUHQRWLQGLFDWHGIRUWKHWUHDWPHQW RIDFQHYXOJDULV VHH6HFWLRQ   7RSLFDOWUHDWPHQWV  ,QDGGLWLRQWRWKHVWXG\GUXJWKHIROORZLQJ SURGXFWVDUHDXWK RUL]HGRQWKHWUHDWHGDUHDVLI WKH\DUHQRWLQGLFDWHGIRUWKHW UHDWPHQWRI$FQH9XOJDULV  3URKLELWHGFRQFRPLWDQWWKHUDSLHVCCI CCI CCI"
29,page_29,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI ,ISURKLELWHGWKHUDSLHVEHFRPHDQHFHVVDU\WUHDWPHQWIRUWKHVD IHW\RUEHVWLQWHUHVWRIWKHVXEMHFW *$/'(50$VKRXOGEHQRWLILHGWRGLVFXVVSRVVLEOHDOWHUQDWLYHVSU LRUWRDGPLQLVWUDWLRQRID SURKLELWHGWKHUDS\ ,IDVXEMHFWUHFHLYHVSURKLELWHGWKHUDS\GXULQJWKHFOLQLFDOWU LDO*$/'(50$VKRXOGEHQRWLILHG WRGLVFXVVWKHSHUWLQHQFHDQGW KHPRGDOLWLHVIRUWKHVXEMHFWWR FRQWLQXHLQWKHFOLQLFDOWULDO 3URFHGXUHVUHDVRQVIRUVXEMHFWGLVFRQWLQXDWLRQ $Q,QYHVWLJDWRUPD\GHFLGHWRGL VFRQWLQXHDVXEMHFWIURPWKHFO LQLFDOWULDOIRUVDIHW\UHDVRQV $OWKRXJKWKHLPSRUWDQFHRIFRPSO HWLQJWKHHQWLUHFOLQLFDOWULDO VKRXOGEHH[SODLQHGWRWKHVXEMHFW E\WKHFOLQLFDOWULDOSHUVRQQHODQ\VXEMHFWLVIUHHWRGLVFRQW LQXHKLVKHUSDUWLFLSDWLRQLQWKLVFOLQLFDO WULDODWDQ\WLPHDQGIRUZKDWHYHUUHDVRQVSHFLILHGRUXQVSHFL ILHGDQGZLWKRXWDQ\SUHMXGLFH1R FRQVWUDLQWVDUHWREHLPSRVHGRQ WKHVXEMHFWDQGZKHQDSSURSUL DWHDVXEMHFWPD\EHWUHDWHGZLWK RWKHUFRQYHQWLRQDOWKHUDS\ ZKHQFOLQLFDOO\LQGLFDWHG :KHQDVXEMHFWGRHVQRWFRPSOHWH WKHFOLQLFDOWULDOKHVKHZLO OEHIXOO\DVVHVVHGLIVXFKDVVHVVPHQW LV SRVVLEOH 7KH SURFHGXUHV GHVLJQDWHG IRU WKH :HHN (DUO\ 7H UPLQDWLRQ YLVLW VKRXOG EH FRPSOHWHGIRUDOOVXEMHFWVGLVF RQWLQXLQJWKHFOLQLFDOWULDODQG WKHDSSURSULDWH&5)SDJHVKRXOGEH FRPSOHWHG $OOGLVFRQWLQXDWLRQVDQGWKHUHDV RQIRUGLVFRQWLQXDWLRQDUHWR EHGRFXPHQWHGE\WKH,QYHVWLJDWRU RQWKH([LW)RUPDQGDOVRRQWKH$ GYHUVH(YHQW)RUPIRUGLVFRQ WLQXDWLRQGXHWRDQ$( )RUGLVFRQWLQXDWLRQGXHWRDQ$( WKH,QYHVWLJDWRUVKRXOGHQVXU HWKDWWKHVXEMHFWUHFHLYHVVXLWDEOH WKHUDS\IRUKLVKHU$( $VXEMHFWZKRKDVEHHQHQUROOH GDQGDVVLJQHGDNLWQXPEHUFDQQR WEHUHSODFHGE\DQRWKHUVXEMHFW LIKHVKHGLVFRQWLQXH VWKHFOLQLFDOWULDOIRUDQ\UHDVRQ *$/'(50$5 'PD\DOVRGHFLGHWR SUHPDWXUHO\WHUPLQDWHRUVXVSHQ GDVXEMHFW¶VSDUWLFLSDWLRQ LQWKHFOLQLFDOWULDO 3RWHQWLDOUHDVRQVIRUGLVFRQ WLQXDWLRQDVOLVWHGRQWKH([LW)R UPDUHGHILQHGLQ7DEOHEHORZ CCI"
30,page_30,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 31 of 88 Table 3 Exit Form reasons for discontinuation Pregnancy: Withdraw the Subject from t he clinical trial and follow the procedure described in Section 7.2.2.2.5 . Lack of Efficacy: Investigator judgment only: based on therapeutic/disease -state expectations. If subject opinion only, mark “subject request” and document it in the comment section of the Exit Form. Adverse Event: Complete an Adverse Event Form. Subject Requesta: Includes consent withdrawal, subject relocation, schedule conflicts. Explain the reason for withdrawal in the comment section of the Exit Form. If a subject withdraws consent because of an adverse event, the reason for discontinuation should be Adverse Event Protocol Violation: Explain the v iolation in the comment section of the Exit Form. Lost to Follow -up: Confirmed with two documented phone calls and a certified letter (delivery receipt requested) without answer. Explain in the comment section of the Exit Form. Othera: This category is t o be used for a subject who discontinues due to a reason other than as specified in the predefined categories above. Explain the reason for discontinuation in the comment section of the Exit Form. a) If reason for discontinuation is “subject request” or “other”, the subject will be questioned to rule out the possibility of an AE (this should be documented in the comment section of the Exit Form)."
31,page_31,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI &/,1,&$/6833/,(6 &OLQLFDOVXSSO\LGHQWLILFDWLRQDQGXVH 6WXG\GUXJGHVFULSWLRQ 7DEOH 'HVFULSWLRQDQG XVDJHRIWKHVWXG\GUXJ  ,QYHVWLJDWLRQDO3URGXFW 7UDGH1DPHRU(TXLYDOHQW 1$ 1DPHRI'UXJ6XEVWDQFH 7ULIDURWHQH ,QWHUQDO&RGH  3KDUPDFHXWLFDO)RUP &UHDP 6WUHQJWK&RQFHQWUDWLRQ PJJ /RFDWLRQRI7UHDWHG $UHD)DFHDQGWUXQFDOUHJLRQ   1$ QRWDSSOLFDEOH   CCI CCI CCICCI"
32,page_32,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6XEMHFWLGHQWLILFDWLRQQXPEHU 8SRQVLJQDWXUHRIWKH,&) DQG $VVHQWIRUPLQRUVXEMHFWV HDFK VXEMHFWZLOOEHDVVLJQHGD6XEMHFW ,GHQWLILFDWLRQ1XPEHU 6,1 E\W KHGHVLJQDWHGVWXG\SHUVRQQHO .LWQXPEHU 7KHNLWQXPEHUDXQLTXHQXPEHUFRUUHVSRQGLQJWRWKHQXPEHURQ WKHODEHORIWKHVWXG\GUXJZLOO EHDVVLJQHGWRHDFKHOLJLEOHVXEMHFWDW%DVHOLQH   ,QVWUXFWLRQVIRUX VHDQGDSSOLFDWLRQ (DFKVXEMHFWZLOOUHFHLYHERWKRUDODQGZULWWHQLQVWUXFWLRQVIR UWKHSURSHUGRVLQJDQGVWXG\ WUHDWPHQWDSSOLFD WLRQWHFKQLTXHV   $VZHOOWKHGRVLQJFDOHQGDUFRPSOHWLRQZLOOEHH[SODLQHGWRH DFK VXEMHFWDWHDFKGLVSHQVDWLRQYLVLW $SSOLFDWLRQVZLOOEHGRQHE\WKHVXEMHFWVWKHPVHOYHVDWKRPHLQ WKHHYHQLQJ    $SSOLFDWLRQRQWKHIDFH CCI CCI CCI CCI CCI CCI"
33,page_33,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 7KHVWXG\GUXJZLOOEHDSSOLHGWRWKHIDFLDOUHJLRQZKLFKLQFOX GHVWKHIRUHKHDGQRVHFKLQDQG HDFKFKHHNRQFHGDLO\LQWKHHYHQLQJDIWHUZDVKLQJDQGGU\LQJ 7KHREMHFWLYHLVWRFRYHUWKHIDFHZLWKDWKLQOD\HURIWKHVWX G\GUXJ  2QHSXPSDFWXDWLRQVKRXOGEHHQRXJK WRFRYHUWKHIRUHKHDGULJKWFKHHNOHIWFKHHNQRVHDQGFKLQ $YRLGDSSOLFDWLRQLQFORVHWRH\HV RUDQJOHVRIWKHPRXWKOLS VDQGPXFRXVPHPEUDQH  $SSOLFDWLRQRQ WKHWUXQN  7KHVWXG\GUXJZLOOEHDSSOLH GWRWKHXSSHUWUXQFDOUHJLRQV   RQFHGDLO\LQWKHHYHQL QJDIWHUZDVKLQJDQGGU\LQJ 7KHREMHFWLYHLVWRFRYHUWKHUHDFKDEOHXSSHUWUXQFDOUHJLRQZL WKDWKLQOD\HURIWKHVWXG\GUXJ 7ZRDFWXDWLRQVRI WKHSXPSVKRXOGEHHQRXJKWRFRYHUULJKWDQGOHIWXSSHUEDFNDU HD  DQGXSSHUDQWHULRUULJKWDQGOHIWFKHVW$YRLGDSSOLFDWLRQRQ WKH D[LOODU\UHJLRQDQGDQWHUL RUDQGSRVWHULRUQHFN 7KHVWXG\GUXJVKRXOGQRWEHDSSOLH GWRFXWVDEUDVLRQVHF]HPD WRXVRUVXQEXUQHGVNLQ 7KHGDLO\GDLU\LVWREHFRPSOHWHGE\WKHVXEMHFW LIQHHGHGZ LWKWKHKHOSRIWKHOHJDOJXDUGLDQ  DQGUHWXUQHGWRWKHVLWHDWHDFKVWXG\YLVLW  2WKHUVXSSOLHVCCI CCI CCI CCI CCI CCI CCI CCI
34,page_34,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6WXG\GUXJSDFNDJLQJDQGODEHOLQJ (DFKVXEMHFWNLWLVFRPSULVHGRIDQRXWHUER[HQFORVLQJ GLVSHQ VLQJER[HVODEHOHGZLWKDQ DIIL[HGDQGDWHDURIISRUWLRQ (DFKGLVSHQVLQJER[ZLOOFRQWDL Q SXPSVDOVRZLWKODEHOLQJ 7KHODEHOVZLOOEHSULQWHGLQWKHORFDOODQJXDJH7KHWH[WRIW KHODEHOZLOOGHWDLOWKHLQIRUPDWLRQ UHTXHVWHGE\*RRG0DQXIDFWXULQJ3U DFWLFHDQGORFDOUHJXODWLRQV  6XSSOLHVPDQDJHPHQW $FFRXQWDELOLW\ 8SRQUHFHLSWRIWKHVWXG\GUXJWKHVLWHSHUVRQQHOUHVSRQVLEOH IRUPDQDJLQJWKHVXSSOLHVPXVW FRQGXFWDFRPSOHWHLQYHQWRU\RIDOOVWXG\GUXJV 7KHLQYHVWLJDWRURUGHVLJQHHZLOOPDLQWDLQDFFXUDWHUHFRUGVRI VXSSOLHVUHFHLYHGLQYHQWRULHGDWWKH FOLQLFDOWULDOVLWH DQGXVHGSHUVXEMHFW $OOVWXG\GUXJVHQWWRWKH,QYHVWLJDWRU,QVWLWXWLRQZLOOEHDFF RXQWHGIRUDQGQRXQDXWKRUL]HGXVHLV SHUPLWWHG    6WRUDJHRIFOLQLFDOVWXG\GUXJCCI CCI CCI CCI CCI CCI"
35,page_35,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6WXG\GUXJPXVWEHVWRUHGLQDV DIHDQGVHFXUHDUHDZLWKUHVWUL FWHGDFFHVV XQGHUWKHVWRUDJH FRQGLWLRQVVSHFLILHGE\*$/'(50$5 ' VHH 7DEOH  'LVSHQVLQJDQGUHWXUQ 'LVSHQVLQJ 'HVLJQDWHGVWXG\SHUVRQQHODWHDFKLQYHVWLJDWLRQDOVLWHZLOOEH UHVSRQVLEOHIRUGLVSHQVLQJWKHVWXG\ GUXJDWWKHDSSURSULDWHYLVLWV DQGZLOOUHFRUGWKHGLVSHQVLQJL QIRUPDWLRQIRUHDFKVXEMHFW 5HWXUQ (DFKVXEMHFWZLOOEHLQVWUXFWHGRQWKHLPSRUWDQFHRIUHWXUQLQJ WKHLUVWXG\GUXJERWWOHSXPSV XVHG DQGRUXQXVHG  'UXJDFFRXQWDELOLW\ZLOOEHGRQHXSRQUHWXUQE\WKHGHVLJQDWHGF OLQLFDOWULDOFHQWHUSHUVRQ QHO )RUVXEMHFWVZKRGRQRWFRPSOHWH WKHHQWLUHFOLQLFDOWULDODOO XVHGDQGXQXVHGVWXG\GUXJVKRXOG EHUHWXUQHGE\WKHVXEMHFWVWRW KHGHILQHGSHUVRQQHODWWKHFOL QLFDOWULDOFHQWHU 7UHDWPHQWFRPSOLDQFHPDQDJHPHQWDQGUHFRUG 6XEMHFWVZLOOEHLQVWUXFWHGE\VWXG\SHUVRQQHORQWKHLPSRUWDQF HRIEHLQJFRPSOLDQWZLWKWKHXVH RIWKHVWXG\GUXJWKURXJ KRXWWKHFOLQLFDOWULDO $VXEMHFWGDLO\GLDU\ZLOOEHSURYLGHGWRWKHVXEMHFWZLWKFOHD UGLUHFWLRQIURPWKHVWXG\VLWH SHUVRQQHODWHDFKGLVSHQVDWLRQYLVLW(DFKVXEMHFWZLOOFRPSOHW HWKHGDLO\GLDU\  6XEMHFWV ZLOODOVREHTXHVWLRQHGDERXWWKH QXPEHURIPLVVHGDSSOLFDWLRQV  LIDQ\ EHWZHHQVWXG\YLVLWVCCI CCI CCI CCI
36,page_36,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 7UHDWPHQWFRPSOLDQFHZLOOEHDVVHVVHGXVLQJWKHVXEMHFWGDLO\G LDU\      'RVHPRGLILFDWLRQ 6XEMHFWVDUHHQFRXUDJHGWRXVHIURPWKH%DVHOLQHYLVLWDQGWKUR XJKRXWWKHVWXG\WKHSURYLGHG PRLVWXUL]HU    6LJQVDQGV\PSWRPVRIORFDOFXWDQHRXVLUULWDWLRQDVVHVVHGZLWK DORFDOWROHUDELOLW\VFDOHZLOOEH FRQVLGHUHGDV$GYHUVH(YHQWV   &/,1,&$/75,$/$66(660(17 (IILFDF\DVVHVVPHQWV ,*$DQG3*$DVVHVVPHQWVDUHWR EHSHUIRUPHGE\DTXDOLILHGHYDO XDWRU  (IILFDF\PHDVXUHPHQWV ,*$3*$DQG/HVLRQ&RXQWVZLOOEHSHUIRUPHGIRUIDFHDQGWUXQN VHSDUDWHO\  5HIHUWR$SSHQGL[ CCI CCI CCI CCI CCI CCI CCI"
37,page_37,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI ,*$ ,QYHVWLJDWRU¶VJOREDOD VVHVVPHQW RII DFLDODFQH 7KHDUHDVGHILQHGIRU,*$DVVHVVPHQWDUHIRUHKHDGHDFKFKHHN FKLQDQGQRVH,*$ZLOOEH FRQILQHGWRDJOREDODVVHVVPHQ WRIHDFKDUHDGHILQHGDERYH 7KH,*$ZLOOEHDVVHVVHG  DFFRUGLQJWRWKHIROORZLQJVFDOH  ,QYHVWLJDWRU¶V*OREDO$VVHVVPHQW6FDOH ,*$ )DFH  &OHDU &OHDUVNLQZLWKQRLQIODPPDWRU\RUQRQLQIODPPDWRU\OHV LRQV  $OPRVW&OHDU $IHZVFDWWHUHGFRPHGRQHVDQGDIHZVPDOOSDSXOH V  0LOG (DVLO\UHFRJQL]DEOH OHVVWKDQKDOIWKHVXUIDFHLVLQYRO YHG6RPHFRPHGRQHVDQGVRPH SDSXOHVDQGSXVWXOHV  0RGHUDWH 0RUHWKDQKDOIRIWKHVXUIDFHLVLQYROYHG0DQ\FRPH GRQHVSDSXOHVDQGSXVWXOHV2QH QRGXOHPD\EHSUHVHQW  6HYHUH (QWLUHVXUIDFHLVLQYROYHG&RYHUHGZLWKFRPHGRQHVQX PHURXVSDSXOHVDQGSXVWXOHV )HZQRGXOHVPD\EHSUHVHQW 3*$ 3K\VLFLDQ*OREDO$VVH VVPHQW RIWUXQFDODFQH 7KHDUHDVGHILQHGIRU3*$DVVHVVPHQWDUHVKRXOGHUVXSSHUEDFN DQGXSSHUDQWHULRUFKHVWZKLFK DUHDFFHVVLEOHWRVHOIDSSOLFDWLRQE\WKHVXEMHFWLHWKHUH JLRQVWKDWWKHVXEMHFWFDQHDVLO\UHDFK DQGDSSO\WKHVWXG\GUXJZLWKRXWDVVLVWDQFH    3*$ZLOOEHFRQILQHGWRDJOREDODVVHVVPHQWRIHDFKDUHDVGHILQ HGDERYH7KH3*$LVDVQDSVKRW VWDWLFDVVHVVPHQWWREHGRQHSUL RUWRGHWDLOHGOHVLRQFRXQWV   CCI CCI CCI CCI CCI"
38,page_38,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJH RI 7KH3*$LVRXWOLQHGLQWKHIROORZLQJWDEOH   3K\VLFLDQ*OREDO$VVHVVPHQW6FDOH 3*$ 7UXQN   &OHDU &OHDUVNLQZLWKQRLQIODPPDWRU\RUQRQLQIODPPDWRU\OHV LRQV  $OPRVW&OHDU $IHZVFDWWHUHGFRPHGRQHVDQGDIHZVPDOOSDSXOH V  0LOG (DVLO\UHFRJQL]DEOH OHVVWKDQKDOIWKHVXUIDFHLVLQYRO YHG6RPHFRPHGRQHVDQGVRPH SDSXOHVDQGSXVWXOHV  0RGHUDWH 0RUHWKDQKDOIRIWKHVXUIDFHLVLQYROYHG0DQ\FRPH GRQHVSDSXOHVDQGSXVWXOHV2QH QRGXOHPD\EHSUHVHQW  6HYHUH (QWLUHVXUIDFHLVLQYROYHG&RYHUHGZLWKFRPHGRQHVQX PHURXVSDSXOHVDQGSXVWXOHV )HZQRGXOHVPD\EHSUHVHQWCCI CCI
39,page_39,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI (IILFDF\HQGSRLQWV (IILFDF\(QGSRLQW 7KHHIILFDF\ HQGSRLQWFRQVLVWVRIWKHIROORZ LQJ  x6XFFHVV5DWHGHILQHGDVWKHSHUFHQWDJHRIVXEMHFWVZKRDFKLHYH DQ,*$VFRUHRI $OPRVW &OHDU RU &OHDU $1'DWOHDVWD JUDGHLPSURYHPHQWIURP%DV HOLQHWR:HHNDQG:HHN CCI CCI"
40,page_40,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI x6XFFHVV5DWHGHILQHGDVWKHSHU FHQWDJHRIVXEMHFWVZKRDFKLHYH D3*$VFRUHRI $OPRVW &OHDU RU &OHDU $1'DWOHDVWD JUDGHLPSURYHPHQWIURP%DV HOLQHWR:HHNDQG:HHN  x3HUFHQWFKDQJHLQIDFLDOQRQ±LQI ODPPDWRU\OHVLRQFRXQWVIURP%D VHOLQHWRZHHNDQGZHHN  x3HUFHQWFKDQJHLQIDFLDOLQIODPPDWRU\OHVLRQFRXQWVIURP%DVHOL QHWRZHHNDQGZHHN x3HUFHQWFKDQJHLQWUXQFDOQRQLQ IODPPDWRU\OHVLRQFRXQWVIURP% DVHOLQHWRZHHNDQG ZHHN x3HUFHQWFKDQJHLQWUXQFDOLQIODPPDWRU\OHVLRQFRXQWVIURP%DVHO LQHWRZHHNDQG:HHN  6DIHW\DVVHVVPHQW 7KHVDIHW\SDUDPHWHUVDUHWKHUHFRUGLQJRIDGYHUVHHYHQWVDQGO RFDOWROHUDELOLW\VFRUHVDVVSHFLILHG LQVHFWLRQ  /RFDOWROHUDELOLW\DVVHVVPHQW RIIDFHDQGRIWUXQN  (U\WKHPDVFDOLQJGU\QHVVZLOOEHHYDOXDWHGE\WKHLQYHVWLJDWR UVHSDUDWHO\RQWKHIDFHDQGWUXQN 7KHVHWROHUDELOLW\VLJQVDQGV\PSWRPVZLOOEHDVVHVVHGIRUWKH IDFHDQGWKHWUXQNVHSDUDWHO\DQG ZLOOEHJUDGHGDWED VHOLQHDQGDWHDFKI ROORZXSYLVLWEDVHGRQ WKHEHORZVFDOH  (U\WKHPD±DEQRUPDOUHGQHVVRIWKHVNLQ 1RQH  1RHU\WKHPD 0LOG  6OLJKWSLQNQHVVSUHVHQW 0RGHUDWH  'HILQLWHUHGQHVVHDVLO\UHFRJQL]HG 6HYHUH  ,QWHQVHUHGQHVV 6FDOLQJ±DEQRUPDOVKHGGLQJRIWKHVWUDWXPFRUQHXP 1RQH  1RVFDOLQJCCI CCI CCI"
41,page_41,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 0LOG  %DUHO\SHUFHSWLEOHVKHGGLQJQRWLFHDEOHRQO\RQOLJKWVFUDWFKLQ JRUUXEELQJ 0RGHUDWH  2EYLRXVEXWQRWSURIXVHVKHGGLQJ 6HYHUH  +HDY\VFDOHSURGXFWLRQ 'U\QHVV±EULWWOHDQGRUWLJKWVHQVDWLRQ 1RQH  1RGU\QHVV 0LOG  6OLJKWEXWGHILQLWHURXJKQHVV 0RGHUDWH  0RGHUDWHURXJKQHVV 6HYHUH  0DUNHGURXJKQHVV 6WLQJLQJ%XUQLQJ±SULFNLQJSDLQVHQVDWLRQLPPHGLDWHO\DIWHUGR VLQJ 1RQH  1RVWLQJLQJEXUQLQJ 0LOG  6OLJKWZDUPWLQJOLQJVWLQJLQJVHQVDWLRQ QRWUHDOO\ERWKHUVRPH  0RGHUDWH  'HILQLWHZDUPWLQJOLQJVWLQJLQJVHQVDWLRQWKDWLVVRPHZKDWERW KHUVRPH 6HYHUH  +RWWLQJOLQJVWLQJLQJVHQVDWLRQWKDWKDVFDXVHGGHILQLWHGLVFR PIRUW $GYHUVHHYHQWV $GYHUVHHYHQWVDUHWREHPRQLWRUHGWKURXJKRXWWKHFRXUVHRIWKH FOLQLFDOWULDO$OO$(VDUHWREH UHSRUWHGRQWKH$GYHUVH(YHQW)R UPZLWKFRPSOHWHLQIRUPDWLRQDV UHTXLUHG,I$(VRFFXUWKHPDLQ FRQFHUQZLOOEHWKHVDIHW\RIWKHVXEMHFWV$WWKHWLPHRIWKH ,&)VLJQDWXUHHDFKVXEMHFWPXVWEH SURYLGHGZLWKWKHQDPHDQGSKRQHQXPEHURIFOLQLFDOWULDOFHQWH USHUVRQQHOIRUUHSRUWLQJ$(VDQG PHGLFDOHPHUJHQFLHV 'HILQLWLRQV $GYHUVHHYHQWVCCI"
42,page_42,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 43 of 88 According to ICH E2A, an AE is any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can the refore be any unfavorable and unintended sign (including an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. Thus any new sign, symptom or disease, or any clinically significant worsening of an existing sign, symptom or disease compared to the condition at the first visit (including disease treated), should be considered as an AE. Lack of efficacy is not considered a s an AE. Each new episode of a chronic disease (e.g., hay fever, allergy, etc.) should be reported as a new AE. Notes:  Any new sign or symptom reported by the subject that appears after accidental or intentional overdose or misuse should also be reported a s an AE.  There should be an attempt to report a diagnosis rather than the signs, symptoms or abnormal laboratory values associated with the report of an AE. However, a diagnosis should be reported only if, in the Investi gator’ s judgment, it is relatively c ertain. Otherwise, symptoms, signs, or laboratory values should be used to describe the AE.  Pregnancy is not to be considered as an AE; however, is an important medical event that must be monitored as described in Section 7.2.2.2.5. 7.2.2.1.2 Serious Adverse events A serious adverse event (SAE) is any untoward medical occurrence that at any dose:  Results in death,  Is life -threatening,  Requires inpatient hospi talization or prolongation of existing hospitalization,  Results in persistent or significant disability/incapacity, or  Is a congenital anomaly/birth defect. Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered an SAE when, based upon appropriate medical judgment, they may jeopardize the safety of the subject and may require medical or surgical intervention to prevent one of the outcomes listed in this definition. Examples of suc h events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasia, or convulsions that do not result in hospitalization."
43,page_43,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 1RWH  7KHWHUP³OLIHWKUHDWHQLQJ´UHIHUVWRDQHYHQWLQZKLFKWKHVXE MHFWZDVDWULVNRIGHDWKDWWKHWLPH RIWKHHYHQW LWGRHVQRWUHIHUW RDQHYHQWWKDWK\SRWKHWLFDOO\ PLJKWKDYHFDXVHGGHDWKLILWZDVPRUH VHYHUH ,QSDWLHQWKRVSLWDOL]DWLRQLVFRQV LGHUHGWRKDYHRFFXUUHGLIWKH VXEMHFWKDVKDGWRVWD\IRUDQLJKWDW WKHKRVSLWDO7KHFULWHULRQIRU SURORQJDWLRQRIKRVSLWDOL]DWLRQ LVDOVRGHILQHGDVDQH[WUDQLJKWDW WKHKRVSLWDO+RVSLWDOL]DWLRQPD\QRWFRQVWLWXWHVXIILFLHQWJUR XQGVWREHFRQVLGHUHGDVDQ6$(LILW LVVROHO\IRUWKHSXUSRVHRIDGLDJQRVWLFWHVWV HYHQLIUHODWH GWRDQ$( HOHFWLYHKRVSLWDOL]DWLRQIRU DQLQWHUYHQWLRQWKDWZDVDOUHDG \SODQQHGEHIRUHVXEMHFWHQUROOP HQWLQWKHFOLQLFDOWULDODGPLVVLRQ WRDGD\FDUHIDFLOLW\VRFLDODGPLVVLRQ HJLIWKHVXEMHFW KDVQRSODFHWRVOHHS RUDGPLQLVWUDWLYH DGPLVVLRQ HJIRUD\HDUO\H[DPLQDWLRQ  $GYHUVH(YHQWVRI6SHFLDO,QWHUHVW $Q$(6,LVDQRWHZRUWK\HYHQWIRUWKHSDUWLFXODUVWXG\GUXJWKD WFDQEHDSSURSULDWHWRPRQLWRU FORVHO\,WFRXOGEHVHULRXVRUQRQVHULRXVDQG$(6,VFRXOGLQF OXGHHYHQWVWKDWPLJKWEHSRWHQWLDO SUHFXUVRUVRUSURGURPDOV\PSWRP VIRUPRUHVHULRXVPHGLFDOFRQGL WLRQVLQVXVFHSWLEOHLQGLYLGXDOV )RU$(6,VWKH,QYHVWLJDWRULV UHTXLUHGWRFRPSOHWHWKH$GYHUVH (YHQW)RUPDQGIROORZWKH$(6, UHSRUWLQJSURFHGXUHVLQ6HFWLRQ HYHQLIWKHHYHQWLVFRQVLG HUHGQRQVHULRXVDFFRUGLQJWR WKHXVXDOUHJXODWRU\FULWHULD)RUVXVSHFWHGVHQVLWL]DWLRQVIRO ORZFKDOOHQJHDQGUHFKDOOHQJHSDWFK WHVWSURFHGXUHVLQ6HFWLRQ  8QH[SHFWHGDGYHUVHGUXJUHDFWLRQ $FFRUGLQJWR,&+(DQXQH[SHFWHGDGYHUVHGUXJUHDFWLRQLVGHI LQHGDVDQDGYHUVHUHDFWLRQWKH QDWXUHRUVHYHULW\RIZKLFKLV QRWFRQVLVWHQWZLWKWKHDSSOLFDE OHVWXG\GUXJLQIRUPDWLRQ HJ,% IRUDQXQDSSURYHGLQYHVWLJDWLRQD OSURGXFWRUWKHSDFNDJHLQVHUW VXPPDU\RISURGXFWFKDUDFWHULVWLFV IRUDQDSSURYHGSURGXFW  $GYHUVHHYHQWUHSRUWLQJSHULRG 7KHFOLQLFDOWULDOSHULRGGXULQJZKLFK$(VPXVWEHUHSRUWHGLV WKHSHULRGIURPZKHQWKHVXEMHFW VLJQHGWKH,&)WRWKHHQGRI WKHVXEMHFW¶VSDUWLFLSDWLRQCCI"
44,page_44,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 45 of 88 The Sponsor should be informed if the Investigator becomes aware of any unusual safety information or any safety information that appears to be drug -related involving a subject who has participated in a clinical trial, even aft er a subject has completed the clinical trial. The Investigator should be diligent in looking for possible latent safety effects that may not appea r until a medication has been discontinued. 7.2.2.1.6 Severity Severity is a clinical determination of the intensity of an AE and not of a disease. The Investigator is to classify the intensity of AEs using the following definitions as a guideline for all AEs occurr ing during clinical trials conducted or sponsored by GALDERMA. For this classification, the Investigator will take into account the possible range of the intensity of the event and report the grade of intensity which is the most appropriate according his m edical judgment. Mild Awareness of signs or symptom, but easily tolerated. Moderate Discomfort, enough to cause interference with usual activity Severe Incapacitating with inability to work or perform usual activity 7.2.2.1.7 Relationship to the study drug The Investigator is to determine whether there is a reasonable causal relationship between the study drug and the AE. Medical judgment should be used to determine the relationship, considering all relevant factors including the pattern of reaction, temporal relationships, positive challenge or rechallenge, relevant medical history, and confounding factors such as co -medication or concurrent diseases. The expression “reasonable causal relationship” is meant to convey in general that there are facts or arguments to suggest a causal relationship (ICH E2A, Section IIIA 1). The relationship assessment for an AE is to be completed using the following definitions as a guideline for all AEs occurring during clinical trials conducted or sponsored by GALDERMA R&D: Reasonable possibility:  According to the reporting Investigator, there is a reasonable possibility (i.e., suggestive evidence or arguments) that there is a causal relationship irrespective of the dose administered between:  The study drug (investigational product and the AE),  The clinical trial protocol procedure (such as blood test) and the AE."
45,page_45,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 46 of 88 No reasonable possibility: No suggestive evidence or arguments can be identified regarding a causal relationship between the study drug or the clinical trial protocol procedure and the AE. 7.2.2.2 Reporting procedures 7.2.2.2.1 Procedures for reporting adverse events The collection of AEs is from the time that a subject signs the ICF to their final visit. At each post -enrollment visit, the Investigator (or sub -Investigator) will question the subject about AEs using an open non- persuasive question to elicit reporting of AEs, for example: “Have you noticed any change in your health since the last visit?” Directed questioning and examination will then be performed, as appropriate. Any AE oc curring during the AE reporting period, whether it is related to the study drug or not, will be recorded immediately in the source document, and described on the Adverse Event Form along with the date of onset, severity, relationship to the study drug, and outcome, without omitting any requested and known information. Additional information may be requested under certain circumstances. Adverse Events assessed as related to the treatment will be monitored until they are completely or satisfactorily resolved. Other AEs will be monitored until the last visit if they are not resolved or satisfactorily resolved. The Investigator will obtain and maintain in the subject’s files all pertinent medical records, information and medical judgment from colleagues who assi sted in the treatment and follow -up of the subject. If necessary, the Investigator will contact the subject’s personal physician or hospital staff to obtain further details. For SAEs (see Section 7.2.2.2.2), AESIs (see Section 7.2.2.2.3), and pregnancies (see Section 7.2.2.2.5), the CSO is to be informed immediately b y fax or email. The event must be reported by facsimile or scan and sent by e- mail to the CSO within 24 hours of knowledge of the event (contact details in Section 7.2.2.2.2). 7.2.2.2.2 Procedure for reporting a Serious Adverse Event For an SAE occurring during the period of the clinical trial, regardless of whether it is related to the treatment or not, and of whether it is expected or not, the Investigator must do the following: 1. Take prompt and appropriate medical action, if necessary. The safety of the subject is the first priority. 2. Immediately inform the CSO of the event by fax or email and discuss further actions to be taken."
46,page_46,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI ,QYHVWLJDWRUFRQWDFW   &RPSOHWHWKH$GYHUVH(YHQW)R UPSURYLGHGLQWKH&5)DVIXOO\ DVSRVVLEOH  (QVXUHWKDWWKHHYHQWLVFOD VVLILHGDVDQ6 $(LQWKH&5)  3ULQWDQGFRPSOHWHWKH6HULRXV $GYHUVH(YHQW)RUPDYDLODEOHL QWKHHOHFWURQLFGDWDFDSWXUH ('& V\VWHPDV3')GRFXPHQW)D[RUVFDQDQGVHQGE\HPDLOW KHFRPSOHWHGIRUP DFFRPSDQLHGE\DQ\RWKHUUHOHYDQW LQIRUPDWLRQRUPHGLFDOUHFRUG V HJODERUDWRU\WHVW UHVXOWV ZLWKLQKRXUVWRWKH&62 7KHGHPRJUDSKLFVPHGLFDO KLVWRU\SUHYLRXVDQG FRQFRPLWDQWWKHUDSLHV DQGDGYHUVHHYHQWSDJHVRIWKH&5)PXVW EHFRPSOHWHGDQG DYDLODEOHIRUUHYLHZLQWKH('&V\VWHPDWWKHWLPHRIWKHUHSRU W  0RQLWRUDQGUHFRUGWKHSURJUH VVRIWKHHYHQWXQWLOLWUHVROYH VRUUHDFKHVDFOLQLFDOO\VWDEOH RXWFRPHZLWKRUZLWKRXWVHTXHODH )RUDOODGGLWLRQDOIROORZXS HYDOXDWLRQVI LUVWLQIRUP WKH&62RIWKHRXWFRPHE\WHOH SKRQHWKHQID[RUVFDQDQGVHQG E\HPDLODOODGGLWLRQDO IROORZXSLQIRUPDWLRQWRWKH&62 ZLWKLQKRXUV6HULRXV$GYHU VH(YHQWVZLOOEH PRQLWRUHGXQWLOWKH,QYHVWLJDWRU DQG6SRQVRUDJUHHWKDWWKHHYH QWLVVDWLVIDFWRULO\UHVROYHG  2EWDLQDQGPDLQWDLQLQKLVKHUI LOHVDOOSHUWLQHQWPHGLFDOUH FRUGVLQIRUPDWLRQDQGPHGLFDO MXGJPHQWVIURPFROOHDJXHVZKRD VVLVWHGLQWKHW UHDWPHQWDQGIRO ORZXSRIWKHVXEMHFW ,IQHFHVVDU\FRQWDFWWKHVXEM HFW¶VSHUVRQDOSK\VLFLDQRUKRVSL WDOVWDIIWRREWDLQIXUWKHU GHWDLOV  ,QIRUPWKH&62RIWKHILQDORXW FRPHRIWKHHYHQW6HQGDUHYL VHGRUXSGDWHG6HULRXV $GYHUVH(YHQW)RUPDQG$GYHUV H(YHQW)RUPLIDSSURSULDWH  &RPSO\ZLWKWKHDSSOLFDEOHUHJ XODWRU\UHTXLUHPHQW V UHODWHG WRWKHUHSRUWLQJRI6$(VWR WKH,QVWLWXWLRQDO5HYLHZ%RDUG ,5% ,QGHSHQGHQW(WKLFV&RPPL WWHH ,(&  3URFHGXUHIRUUHSRUWLQJDQDGYHUVH HYHQWRIVSHFLDOLQWHUHVW )RUDQ\$(6, VHH6HFWLRQ  RFFXUULQJGXULQJWKHSHULRGRI WKHFOLQLFDOWULDOZKHWKHU UHODWHGWRWKHWUHDWPH QWRUQRWDQGZKHWKHUH[SHFWHGRUQRWW KH,QYHVWLJDWRULVWRGRWKHIROORZLQJ   7DNHSURPSWDQGDSSU RSULDWHPHGLFDODFWLRQLIQHFHVVDU\7KH VDIHW\RIVXEMHFWVLVWKHILUVW SULRULW\  ,PPHGLDWHO\LQIRUPWKH&62RI WKHHYHQWE\ID [RUHPDLODQGG LVFXVVIXUWKHUDFWLRQVWREH WDNHQ  ,QYHVWLJDWRUFRQWDFW 5HIHUWR6HFWLRQ   &RPSOHWHWKH$GYHUVH(YHQW)R UPSURYLGHGLQWKH&5)DVIXOO\ DVSRVVLEOH  (QVXUHWKDWWKHHYHQWLVFOD VVLILHGDVDQ$(6,LQWKH&5)  3ULQWWKH$GYHUVH(YHQWIRUP)D[RUVFDQDQGVHQGE\HPDLO WKHFRPSOHWHGIRUP DFFRPSDQLHGE\DQ\RWKHUUHOHYDQW LQIRUPDWLRQRUPHGLFDOUHFRUG V HJODERUDWRU\WHVWPPD"
47,page_47,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI UHVXOWV ZLWKLQKRXUVWRWKH&62 7KHGHPRJUDSKLFVPHGLFDO KLVWRU\SUHYLRXVDQG FRQFRPLWDQWWKHUDSLHV DQGDGYHUVHHYHQWSDJHVRIWKH&5)PXVW EHFRPSOHWHGDQGDYDLODEOH IRUUHYLHZLQWKH('&V\VWHPDWWKHWLPHRIWKHUHSRUW  0RQLWRUDQGUHFRUGWKHSURJUH VVRIWKHHYHQWXQWLOLWUHVROYH VRUUHDFKHVDFOLQLFDOO\VWDEOH RXWFRPHZLWKRUZLWKRXWVHTXHODH )RUDOOWKHDGGLWLRQDOIROOR ZXSHYDOXDWLRQV ILUVWLQIRUP WKH&62RIWKHRXWFRPHE\WHOH SKRQHWKHQID[RUVFDQDQGVHQG WKHDGGLWLRQDOIROORZXS LQIRUPDWLRQE\HPDLOWRWKH &62ZLWKLQKRXUV$(6,VZLOOEH PRQLWRUHGXQWLOWKH ,QYHVWLJDWRUDQG6SRQVRUDJUHHWKDW WKHHYHQWLVVDWLVIDFWRULO\ UHVROYHG  2EWDLQDQGPDLQWDLQLQKLVKHUI LOHVDOOSHUWLQHQWPHGLFDOUH FRUGVLQIRUPDWLRQDQGPHGLFDO MXGJPHQWVIURPFROOHDJXHVZKRD VVLVWHGLQWKHW UHDWPHQWDQGIRO ORZXSRIWKHVXEMHFW ,IQHFHVVDU\FRQWDFWWKHVXEM HFW¶VSHUVRQDOSK\VLFLDQRUKRVSL WDOVWDIIWRREWDLQIXUWKHU GHWDLOV  ,QIRUPWKH&62RIWKHILQDORXW FRPHRIWKHHYHQW6HQGDUHYL VHGRUXSGDWHG$GYHUVH(YHQW )RUPLIDSSURSULDWH 3URFHGXUHVIRUVXVSHFWHGVHQ VLWL]DWLRQ 5H&KDOOHQJHDQGSDWFK ,QJUHGLHQW 7HVW  ,IDVXEMHFWH[SHULHQFHVVXVSHFWHGVNLQVHQVLWL]DWLRQ FRQWDFW DOOHUJ\ WKHIROORZLQJDFWLRQVVKRXOG EHWDNHQWRFKDUDFWHUL]HWKHHYHQW  CCI"
48,page_48,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJH RI 7DEOH 6XVSHFWHGVHQVLWL]DWLRQUHDFWLRQJUDGLQJ 6FRUH 0RUSKRORJ\  ,QWHUSUHWDWLRQ   1RVNLQFKDQJHVLQWKHWHVWHGDUHD 1HJDWLYH "" )DLQWQRQSDOSDEOHHU\WKHPD 'RXEWIXOUHDFWLRQ  3DOSDEOHHU\WKHPD PRGHUDWHHGHPDRULQILOWUDWH SDSXOHVQRW  SUHVHQWRUVFDUFHYHVLFOHVQRWSUHVHQW:HDNSRVLWLYHUHDFWLRQ 6WURQJLQILOWUDWHQXPHURXVSDSXOHVYHVLFOHVSUHVHQW 6WURQJSR VLWLYHUHDFWLRQ (U\WKHPDLQILOWUDWLRQFRQIOXHQWYHVLFOHVEXOODHRUXOFHUDWLR Q ([WUHPHSRVLWLYHUHDFWLRQ LU ,QIODPPDWLRQVKDUSO\OLPLWHGWRWKHH[SRVHGDUHDODFNRILQ ILOWUDWH VPDOOSHWHFKLDHSXVWXOHVDQGHIIORUHVFHQFHVRWKHUWKDQSDSXOH V DQGYHVLFOHV,UULWDQWUHDFWLRQ 1W  1RWWHVWHG $WWKHODVWUHDGLQJWKHLQYHV WLJDWRUZLOOSURYLGHDQLQWHUSUHW DWLRQUHJDUGLQJDSRVVLEOH VHQVLWL]DWLRQUHDFWLRQXVLQJWKHIROORZLQJVFDOH  7DEOH 6XVSHFWHGVHQVLWL]DWLRQFRQFOXVLRQCCI"
49,page_49,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 6HQVLWL]DWLRQ5HDFWLRQ  1HJDWLYH DEVHQFHRIUHDFWLRQRUPLJKWEHLUULWDQWUHDFWLRQ   (TXLYRFDO  3RVLWLYH E ,QFDVHRIVXVSLFLRQRILPPHGLDWH FRQWDFWVNLQUHDFWLRQ VXFKD VXUWLFDULD  $FDVHE\FDVHDSSURDFKZLOOEHDSSOLHGDQGWKHSURFHGXUHWRIR OORZZLOOEHGLVFXVVHGZLWKWKH 6SRQVRU 3URFHGXUHVIRUUHSRUWLQJSUHJQDQFLHV $Q\SUHJQDQF\RFFXUULQJGXULQJF OLQLFDOWULDOVZKHUHWKHIHWXV FRXOGKDYHEHHQH[SRVHGWRWKH VWXG\GUXJPXVWEHPRQLWRUHGXQWLOLWVRXWFRPHLQRUGHUWRHQV XUHWKHFRPSOHWHFROOHFWLRQRIVDIHW\ GDWDRQ*$/'(50$5 'SURGXFWV ,IDVXEMHFWEHFRPHVSUHJQDQWW KH,QYHVWLJDWRULVWRGRWKHIR OORZLQJ  :LWKGUDZWKHVXEMHFWIUR PWKHFOLQLFDOWULDOCCI CCI"
50,page_50,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI  $WWKHRXWFRPHRIWKHSUHJQDQF\FRPSOHWHWKH3UHJQDQF\6XUYH LOODQFH)RUP±3DUW,, &RXUVHDQG2XWFRPHRI3UHJQDQF\ DVIXOO\DVSRVVLEOH,QIRUPW KH&62E\WHOHSKRQHWKHQ ID[RUVFDQDQGVHQGE\HPDLOWK LVSUHJQDQF\IRUPWRWKH&62Z LWKLQKRXUV  ,IWKHSUHJQDQF\OHDGVWRDQDERUWLRQ YROXQWDU\VSRQWDQHRXV RUWKHUDSHXWLF LQXWHUR GHDWKRUFRQJHQLWDODQRPDO\IR OORZWKHSURFHGXUHIRUGHFODUDW LRQRIDQ6$( VHH6HFWLRQ   2WKHUDVVHVVPHQWV 3KRWRJUDSKV CCI"
51,page_51,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI 'HUPDWRORJ\/LIH4XDOLW\,QGH[ '/4, &KLOGUHQ¶V'HUPDWRORJ\ /LIH4XDOLW\ ,QGH[ &'/4,  'HUPDWRORJ\/LIH4XDOLW\,QGH[ F'/4,'/4, ZLOOEHFRPSOHWHGE \WKHVXEMHFWDWWKHEDVHOLQH DQGZHHNDQGHDUO\WHUPLQDWLRQSULRUWRDQ\,QYHVWLJDWRU DVVHVVPHQWVWRQRWLPSDFWWKH VXEMHFW¶VDQVZHUVWRWKHTXDOLW\RIOLIHTXHVWLRQQDLUH6XEMHFW V\HDUVDQG\RXQJHU DWEDVHOLQH  VKRXOGFRPSOHWHWKHF'/4, DQG \HDUVDQGROGHUFRPSOHWHWKH '/4, WKURXJKRXWWKHVWXG\ 3ULRUWRDQ\DFQHDVVHVVPHQWVWKH,QYHVWLJDWRURUGHVLJQHHVKR XOGSURYLGHWKHVXEMHFWZLWKWKHDJH DSSURSULDWH'/4,)RUPDQGLQVWUXFWWKHVXEMHFWWRUHDGDQGDQVZ HUDOOTXDOLW\RIOLIHTXHVWLRQV 7KHGHVLJQDWHGVWXG\SHUVRQQHOZLOOWKHQFKHFNWKHTXHVWLRQQDLU HIRUFRPSOHWHQHVVSULRUWR WKHVXEMHFWOHDYLQJWKHRIILFH  7KLV42/LQVWUXPHQWLVQRWDFQHVSHFLILF7KH'/4,&'/4,DUHY DOLGDWHGLQVWUXPHQWVWKDW PHDVXUHWKHGHUPDWRORJ\UHODWHGOLPLWDWLRQVRIIXQFWLRQDODELOL W\DQGWKHIUHTXHQF\VHYHULW\DQG LPSDFWRIJHQHUDOLQIODPPDWRU\ VNLQFRQGLWLRQVRQWKHTXDOLW\R IOLIH 7KHVL[GRPDLQVDGGUHVVHGL QWKHTXHVWLRQQDLUHDUH  V\PSWRPVDQGIHHOLQJV GDLO\DFWLYLWLHV OHLVXUH ZRUNVFKRRO SHUVRQDOUHODWLRQVKLSV WUHDWPHQW 7KHSRVVLEOHDQVZHUVWRWKH'/4 ,TXHVWLRQVIRUWKHHIIHFWRIDF QHRQ42/ZHUHVFRUHGDV IROORZV YHU\PXFK  DORW  DOLWWOH  DQGQRWDWDOO   7KH'/4,LVFDOFXODWHGE\CCI"
52,page_52,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 53 of 88 summing the scores of each question, resulting in a maximum of 30 and a minimum of 0. A lower score on the DLQI indicated increased QOL; therefore, negative changes from Baseline indicate improvement. The meaning of the DLQI total scores were interpreted as: no effect (0 -1), small effect (2 -5), moderate effect (6 -10), very large effect (11 -20), or extremely large effect (21 - 30). For the cDLQI: The meaning of the DLQI total scores were interpreted as: no effect (0 -1), small effect (2 -6), moderate effect (7 -12), very large effect (13 -18),or extremely large effect (19 -30). The higher the score, the more quality of life is impaired. For instructions of use and scoring: http://sites.cardiff.ac.uk/dermatology/quality -of-life/dermatology -quality -of-life-index-dlqi/dlqi- instructions- for-use- and-scoring The questionnaires completed will be considered as source data and the answers will be entered into the CRF by the site. 7.3.3 CompAQ for Facial and Truncal Acne It will be collected at baseline, week 12 and 24/ early termination. The Investigator or designee should provide the subject (16 years of age and older) with the comprehensive QoL measure inclusive of facial and trun cal form and instruct the subject to read and answer all 20 quality of life questions. The questionnaire will measure the impact of facial and torso acne on health- related quality of life. The 20 questions consists of 5 domains that assess a variety of psychosocial and physical impacts of acne: Psychological/Emotional, Social (Judgement From Others), Social Interactions, Treatment Concerns, Physical Symptoms. The score on the CompAQ has a possible range of 0 to 160. The higher the score, the more quality of life is impaired. F or instructions of use and scoring ( Chelsea McLellan, Marc P. Frey, Diane Thiboutot, Alison Layton, Mary -Margaret Chren, Jerry Tan, Development of a Comprehensive Quality -of-Life M easure for Facial and Torso Acne. Journal of Cutaneous Medicine and Surgery First Published January 31, 2018 https://doi.org/10.1177/1203475418756379) An anchor question is added in order to detect responsivity with intervention and for Minimal Clinically Important Difference (MCID). Higher scores indicate greater adverse impact •The response range for each question is from 0–8 with higher numbers indicating greater adverse impact. •For each domain, response range is from 0 –32. •For the long form questionnaire, response range is from 0–160 •For the short form questionnaire, response range is from 0–40 The investigator or delegate will then check all questions of the questionnaire for completeness prior to the subject leaving the office."
53,page_53,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI (XUR4R/'LPHQVLRQ (4'/  $W EDVHOLQH DQG ZHHNV  DQG (DUO\ WHUPLQDWLRQ VXEMHFW ZLOO  FRPSOHWH WKH (4'/ $SSHQGL[   (4'/LVDYDOLGDWHGTXHVWLRQQDLUHIRUWKHDVVHVVPHQWRIWKH JHQHUDOKHDOWKVWDWH,WFRQWDLQV WZRSDUWV DGHVFULSWLYHV\VWHPDQGD9$67KHGHVFULSWLYHV\VW HPLVPDGHXSRIILYHGLPHQVLRQV  PRELOLW\VHOIFDUHXVXDODFWLYLWLHVSDLQGLVFRPIRUWDQGDQ[L HW\GHSUHVVLRQ7KH9$6FRQVLVWVRI DYHUWLFDOOLQHZKHUHWKHVXEMHFWFDQDVVHVVKLVRUKHURZQKHD OWKVWDWXV(4'/ZLOOEH DGPLQLVWHUHGDFFRUGLQJWRWKHVFKHGXOHRIDVVHVVPHQWVRQO\WRW KHVXEVHWRIVXEMHFWVZKRIOXHQWO\ VSHDNDODQJXDJHLQZKLFKWKHTXHVWLRQQDLUHLVSUHVHQWHG EDVHG RQDYDLODELOLW\RIYDOLGDWHG WUDQVODWLRQVLQSDUWLF LSDWLQJFRXQWULHV  6XEMHFWVDWLVIDFWLRQTXHVWLRQQDLUH  $WZHHNVDQG(DUO\WHUPLQ DWLRQVXEMHFWZLOOFRPSOHWHDV DWLVIDFWLRQTXHVWLRQQDLUHUHJDUGLQJ WKHLQYHVWLJDWLRQDOSURGXFWVWKH\KDYHEHHQXVLQJLQWKLVWULDO  VHH$SSHQGL[     6WXG\GUXJDFFHSWDELOLW\TXHVWLRQQDLUH  $WZHHNVDQG(DUO\WHUPLQD WLRQVXEMHFWVZLOOFRPSOHWHDQ DFFHSWDELOLW\TXHVWLRQQDLUH UHJDUGLQJXVHRIWKHVWXG\GUXJ VHH$SSHQGL[   &/,1,&$/75,$/9,6,76'( 6&5,37,216$1'352&('85(6 'HVFULSWLRQRIFOLQ LFDOWULDOYLVLWV 3OHDVHUHIHUWRWKH6 FKHGXOHRI$VVHVVPHQWVWDEOHLQWKH6\QRSV LV 7DEOH  $ZULWWHQGDWHGLQLWLDOHGDQGVLJQHG,&)$VVHQW)RUPIRUPLQ RUV+,3$$DQG3KRWR&RQVHQW )RUPRU3KRWR$VVHQWIRUPPXVW EHREWDLQHGSULRUWRSHUIRUPLQJ DQ\FOLQLFDOWULDOUHODWHG HYDOXDWLRQVDQGRUSURFHGXUHVCCI CCI CCI"
54,page_54,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
55,page_55,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
56,page_56,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
57,page_57,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
58,page_58,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJH RI CCI
59,page_59,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
60,page_60,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI  8QVFKHGXOHGYLVLWV $QXQVFKHGXOHGYLVLWPD\RFFXUIRUVDIHW\UHDVRQV 'XULQJWKHVHYLVLWVWKHDVVH VVPHQWVZLOOEHFRQGXFWHGDVDSSUR SULDWHGHSHQGLQJRQWKHUHDVRQIRU WKHYLVLWCCI CCI
61,page_61,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI  67$7,67,&$/0(7+2'63/$11(' 6WDWLVWLFDODQDO\VLVSODQ $VWDWLVWLFDODQDO\VLVSODQ 6$3 ZLOOEHGHYHORSHGDQGLVVXHG DVDVHSDUDWHGRFXPHQW7KH6$3 ZLOOFRQWDLQDPRUHGHWDLOHGDQGWHFKQLFDOGHVFULSWLRQRIVSHFL ILFGDWDFRQYHQWLRQVFDOFXODWLRQV DQGRIVWDWLVWLFDOSURFHGXUHVIRUH[HFXWLQJWKHDQDO\VLVVWUDWH JLHVWKDWDUHVSHFLILHGLQWKHVHFWLRQV RIWKHFOLQLFDOWULDORXWOLQHEHORZ7KH6$3ZLOOEHILQDOL]HG SULRUWRWKHGDWDEDVHORFN      $Q\FKDQJHVWRDQDO\VHVPDGHDIWHUWKH6$3KDVEHHQILQDOL]HG DORQJZLWKDQH[SODQDWLRQDVWR ZKHQDQGZK\WKH\RFFXUUHGZLOOEHGRFXPHQWHGLQWKHFOLQLFDO VWXG\UHSRUW3RVWKRFH[SORUDWRU\ DQDO\VHVZLOODOVREHFOHDUO\LGH QWLILHGLQWKH&OLQLFDO6WXG\ 5HSRUW &65  'DWDWUDQVIRUPDWLRQV 1RWDSSOLFDEOHCCI CCI CCI"
62,page_62,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI  3RSXODWLRQVDQDO\]HGHYDOXDELOLW \DQGOLPLWDWLRQHYDOXDWLRQ RIELDV 7KH,QWHQWLRQWR7UHDW ,77 SRSXODWLRQZLOOEHXVHGIRUWKHDQ DO\VHVRIHIILFDF\HQGSRLQWV  'DWDSUHVHQWDWLRQ DQGJUDSKLFV )RUVWDWLVWLFDODQDO\VHVSXUSRVHEDVHOLQHLVGHILQHGDVWKHOD VWPHDVXUHPHQWSULRUWRWKHILUVW DSSOLFDWLRQRIWKHVWXG\GUXJD QGDOODQDO\VHVZLOOEHVXPPDUL] HGE\YLVLWV )RUWKHVXPPDU\VWDWLVWLFVWKHFDWHJRULFDOGDWDZLOOEHVXPPDU L]HGE\IUHTXHQF\DQGSHUFHQWDJH RIVXEMHFWVIRUHDFKUHVSRQVHFDWHJRU\ 1 DQGWKHFRQWLQXRX VGDWDZLOOEHVXPPDUL]HGXVLQJ QXPEHURIVXEMHFWVPHDQPHGLD QPLQLPXPPD[LPXPDQGVWDQGDU GGHYLDWLRQCCI CCI"
63,page_63,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 64 of 88 Subject disposition, demographics and baseline characteristics, previous therapies, and concomitant therapies will be summarized by descriptive statistics based on the ITT Population. Treatment exposure and compliance data will be summarized based on the Safety Population. For statistical analysis purposes, previous therapies/procedures are defined as those ending at Baseline or before; and concomitant therapies/procedures are defined as those ongoing at the Baseline visit or starting after the Baseline visit. Treatment -emergent Adverse Events (TEAEs) are defined as AEs with onset on or after first dose of study drug; or those AEs with onset prior to first dose of study drug but worsened during treatment. TEAEs will be tabulated in frequency tables by System Organ Class (SOC) and Preferred Term (PT) based on the Medical Dictionary for Regulatory Activities (MedDRA). Additional summary tables will be provided for SAEs, AEs considered related to the study drug, severe AEs, AESIs, and AEs leading to discontinuation. For a given AE, a subject will be counted once even if he/she has experienced multiple episodes of that particular AE. In addition, non TEAEs will be summarized or listed separ ately. For local tolerability (erythema, scaling, dryness, stinging/burning), data will be summarized for worst score over treatment period, the final score during treatment, as well as scores for each visit. The quality of life indices, EQ-5D- 5L, COMPAQ ( including the anchor question), C-DLQI, and DLQI will be summarized descriptively. Subgroup analyses will be explored by analysis center, age (<18 years, ≥18 years), gender and race if appropriate for efficacy endpoint, and safety endpoints (TEAEs and Loca l tolerability). Further details will be provided in the SAP. 9.1.3.1 Imputation of missing data The last observation carried forward (LOCF) will be used to impute efficacy endpoints, where applicable. Non- responder analysis will also be carried out for Binary endpoints. Further details will be provided in the SAP. 9.1.3.2 Statistical hypothesis testing and multiplicity adjustment Analysis of Efficacy Endpoint All efficacy and patient reported endpoints will be summarized with point estimate a nd 95% confidence intervals. Further details will be provided in SAP."
64,page_64,"*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI  6DPSOHVL]HGHWHUPLQDWLRQ 7KHUHLVQRIRUPDOK\SRWKHVLVWREHWHVWHG$QHVWLPDWLRQDSSUR DFKZLOOEHSHUIRUPHG3RLQW HVWLPDWHDQG FRQILGHQFHLQWHUYDOZLOOFRQVWUXFWHG$SSUR[LP DWHO\VXEMHFWVZLOOEHHQUROOHG WRHYDOXDWHWKHVXEMHFWUHSRUWH GRXWFRPHV TXDOLW\RIOLIHDQG VDWLVIDFWLRQVXUYH\  75$,1,1*021,725,1*'$7$ 0$1$*(0(174 8$/,7<$6685$1&( 3HUVRQQHOWUDLQLQJ ,QYHVWLJDWRUVWUDLQLQJZLOORFFXURQVLWHGXULQJWKHVLWHLQLWL DWLRQYLVLW,WLVUHFRPPHQGHGWKDWDOO LQYHVWLJDWRUVRWKHUHYDOXDWRUV VWXG\FRRUGLQDWRUVDQGRWKHUD SSOLFDEOHSHUVRQQHODWWHQGWKHVLWH LQLWLDWLRQYLVLW'XULQJWKHVHPHHWLQJVWUDLQLQJV  $OOVLWHVPXVWFRPSOHWHSKRWRJUDSK\WUDLQLQJDQGVXEPLWWHVWSK RWRVRIDOOUHTXLUHGOLJKWFRQGLWLRQV  7KH,QYHVWLJDWRUVDQGVWXG\FRRU GLQDWRUVDUHH[SHFWHGWRDWWHQG WKH,QYHVWLJDWRUUHFHLYHRQVLWH WUDLQLQJGXULQJWKHVLWHLQLWLDWLRQYLVLWSULRUWRSDUWLFLSDWLQ JLQWKHSURFHGXUHVDQGHYDOXDWLRQVLQ WKLVVWXG\(DFKVLWHZLOOKDYHDWUDLQLQJUHFRUGDVSDUWRIWK HVLWHILOHDQG7ULDO0DVWHU)LOH$Q ,QYHVWLJDWRU6LWH)LOHZLOOEHSU RYLGHGWRHDFKVWXG\FHQWHU $VWXG\LQLWLDWLRQYLVLWZLOOEHFRQGXFWHGIRUHDFKVWXG\FHQWH USULRUWRHQUROOPHQWRIDQ\VXEMHFWV &5$VDQGRWKHUDSSOLFDEOHSHUV RQQHOZLOOEHWUDLQHGSULRUWRVW XG\LQLWLDWLRQWRIDPLOLDUL]H&5$V ZLWKWKHGLVHDVHWKH6WDQGDUG2 SHUDWLQJ3URFHGXUHV 623 WKH SURWRFRODQGRWKHUVWXG\VSHFLILF LWHPV7HDPRUJDQL]DWLRQFRPPXQL FDWLRQDQGRSHUDWLRQDOLVVXHV ZLOODOVREHGLVFXVVHG &OLQLFDOPRQLWRULQJ 7KH FRQGXFW RI WKH FOLQLFDO WULDO  ZLOO EH FORVHO\ PRQLWRUHG E\ UHSUHVHQWDWLYHV RI *$/'(50$5 'DQGRU&RQWUDFW5HVHDUFK2UJDQL]DWLRQ &52 WRYHU LI\DGKHUHQFHWRWKH FOLQLFDOWULDOSURWRFRO,&+*& 3JXLGHOLQHVDQGDSSOLFDEOH623 VVWXG\SURFHGXUHVCCI CCI CCI"
65,page_65,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 66 of 88 The Investigator will allow the CRO / Sponsor’s representatives, to h ave direct access to all clinical trial records, CRFs, corresponding subject medical records, study drug dispensing records, study drug storage area, clinical trial facilities, and any other documents considered source documentation. The Investigator also agrees to assist the representative if required. 10.3 Data management The designated CRO will be responsible for activities associated with the data management of this study. This will include, but not limited to, setting up a relevant database and data transfer mechanisms, along with appropriate validation of data and resolution of queries. Study sites will enter data directly into an electronic data capture (EDC) system by completing the CRF via a secure internet connection. Data entered into the CRF m ust be verifiable against source documents at the study center. Data to be recorded directly on the CRF will be identified and the CRF will be considered the source document. Any changes to the data entered into the EDC system will be recorded in the audit trail. All data management activities will be detailed in a Data Management Plan (DMP). 10.4 Quality assurance / audit / inspection The clinical trial is conducted under the sponsorship of GALDERMA R&D in compliance with the applicable international and local regulatory requirements as well as applicable ICH guide lines and in accordance with the SOPs for clinical trial conduct and monitoring from GALDERMA and/or the CRO. At the completion of the study, digital images will be forwarded to the Sponsor according to individual testing facility SOPs. Audits of clinical trial centers may be conducted by the Sponsor/CRO representatives, and inspection may be performed by Regulatory Authority inspectorates or IRBs/IECs before, during, or after the clinical trial. The Investigator will allow and assist the CRO /Sponsor’s representatives, IRBs/IECs and any regulatory agency to have direct access to all requested clinical trial -related records. For the audits performed by, or on behalf of, GALDERMA auditors, audit certi ficate(s) will be provided by Quality Assurance. 10.5 Changes in clinical trial conduct / amendments"
66,page_66,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 67 of 88 10.5.1 Clinical trial conduct With the exception of eliminating an immediate hazard to a subject, the Investigator should not deviate from the clinical trial protocol or implement any changes without written approva l from the Sponsor and prior review and documented approval/favorable opinion from the IRB/IEC of a protocol amendment. Changes that involve only logistical or administrative changes to the clinical trial pro tocol are authorized. The Investigator should document and explain any deviation from the clinical trial protocol. 10.5.2 Amendments The Sponsor may modify the clinical trial protocol at any time for ethical, medical, or scientific reasons . 10.5.3 Attrition Clinical studies may experience attrition. Subjects will be made aware that they are free to withdraw from the study at any time for any reason, without prejudice. Otherwise, every effort will be made to have subjects complete the study as stated in this p rotocol, ensuring subject safety and following the provisions of the ICF. Reasons for subject withdrawal may include an AE, SAE, subject’s request, protocol violation, lost to follow -up, and other reasons. Subjects lost from the study will be documented on a screening/enrollment log. If a subject fails to return for a scheduled examination, a representative of clinical site (site representative/study coordinator) will attempt to contact the subject and determine whether the subject has continued to follow study instructions and intends to continue participation in the study. If so, then the subject will be rescheduled to come into the clinic as soon as possible. If a rescheduled visit is outside of the specified time frame window, this will be recorded in the screening/enrollment log and as a deviation. If a subject cannot reschedule in an acceptable time frame and completely misses 1 study visit, the subject may be allowed to continue study participation at the discretion of the Investigator and the Sponsor, provided that the subject has continued to comply with study instructions. If the subject is allowed to continue, the missed visit will be noted in the screening/enrollment log and recorded as a protocol deviation. Subjects will not be allowed to miss the week 12 visit. 11 ETHICS AND GENERAL CLINICAL TRIAL CONDUCT CONSIDERATIONS"
67,page_67,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 68 of 88 11.1 Institutional Review Board or Independent Ethics Committee This study (protocol, ICF and all addenda) will be reviewed and approved by IntegReview IRB. The study will not b e activated and subjects will not be consented, receive any study products, or participate in any study procedures until such time as the IRB has approved the protocol and the ICF. In addition, the IRB will review the study before any significant change in the protocol is initiated. After each review, the IRB's approval will be documented in a letter to the Investigator and a copy of the IRB approval letter will be forwarded to the Sponsor. 11.2 Ethical conduct of the clinical trial This clinical trial will be conducted in accordance with the protocol , the HELSINKI declaration (1964) and subsequent amendments, and the ICH GCP, and in compliance with applicable regulatory requirements. 11.3 Subject information and consent All subjects who participate in this clinical trial are required to be fully informed about the clinical trial in accordance with GCPs guidelines, federal regulations, HIPAA (if in the US), or applicable local privacy act if in other countries, and guidelines and in accordance with local requirement s. The ICF, Assent Form, HIPAA or other applicable local privacy act), and Photo Consent Form, approved by an IRB/IEC, will be fully explained to the subject. Prior to enrolment into the clinical trial, the subject and as needed, the subject’s parent/legal representative will s ign and date the consent form(s), including assent. The Investigator is responsible for maintaining each subject’s consent form(s) in the Investigator’s site file and providing each subject, and his/her parent legal representative with a copy of the signed and dated consent form(s) including assent. 11.4 Contractual requirements A contractual agreement will be signed between the Sponsor/CRO and each Investigator/Institution. This document will contain supplementary information, including financial terms, confidentiality, the clinical trial schedule, third party responsibility, and publication rights. 11.5 Data collection and archiving 11.5.1 Data collection"
68,page_68,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 69 of 88 The I nvestigator must maintain all required records for all subjects. Data for this clinical trial will be recorded in the subject’s source documents, subject photographs and on the CRFs provided by the Sponsor. All data should be recorded on the CRFs completely and promptly . 11.5.2 Source documentation The Investigator must keep accurate separate record s (other than the CRFs) of all subject visits, being sure to include all pertinent clinical trial- related information. A statement should be made indicating th at the subjects have been included in this clinical trial and have provided signed written Inform ed Consent and Assent as applicable. All AEs must be thoroughly documented. Results of any diagnostic tests conducted during the clinical trial should also be included in the source documentation. 11.5.3 Archives All pertinent data, samples, photographs, correspondence, and reports, the original or amended clinical trial protocol, and all other material relating to the clinical trial will be maintained securely in Sponsor/CRO Investigator/Institution archives for the legally required duration for archiving. The I nvestigator/Institution should maintain the essential clinical trial documents as specified in Section 8 of ICH-GCP, and according to the applicable regulatory requirements. The Investigator/Institution should take measures to prevent accidental or premature destruction of these documents. If the Principal Investigator retires, relocates, or withdraws from the responsibility of keeping the clinical trial records for any other reasons, custody must be transferred to a person who will accept the responsibility. The Sponsor/CRO must be notified in writing of the name and address of the new custodian. 11.6 Insurance A certificate attesting Third Party coverage of Sponsor/CRO will be provided upon request. 12 LITERATURE REFERENCE LIST 1.Canavan TN, Chen E, Elewski BE. Optimizing non- antibiotic treatments for patients with acne: a review. Dermatol Ther . 2016;6(4):1-24. 2.Tsatsou F, Zouboulis CC. Anatomy of the sebaceous gland. In: Zouboulis C, Katsambas A, Kligman, A, eds. Pathogenesis and Treatment of Acne and Rosacea . London, UK: Springer; 2014:27-31."
69,page_69,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 70 of 88 3.Koo J Y, et al. Psychologic aspects of acne. Pediatr Dermatol. 1991; 8:185-8. 4.Osterweil N, ed. Frustrated adults told acne was adolescent disease, survey says. Dermatol Times. 1993;14(suppl):S5-S6. 5.Bayramgurler D, Pelin Kartal S, Altunel, C. Use of topical retinoids in acne. In: Pelin Kartal, ed .Acne and Acneiform Eruptions. London, UK: IntechOpen; 2017: 118-127. 6.Dreno B. Pathophysiology of acne. Presse Medicale. 2005 Apr 9;34(7):537-9. 7.Gollnick H. Current concepts of the pathogenesis of acne: implications for drug treatment. 2003;63(15):1579-1596. 8.Del Rosso JQ. Management of truncal acne vulgaris: current perspectives on treatment. Cutis. 2006 May;77(5):285-9. 9.Joseph Bikowski. Managing Two Challenging Presentations of Acne . Practical Dermatology, March 2011 : 63-65 10.Del R osso JQ, Bikowski JB, Baum E, Smith J, Hawkes S, Benes V, Bhatia N. A closer look at truncal acne vulgaris: prevalence, severity, and clinical significance. J Drugs Dermatol. 2007 Jun;6(6):597-600. 11. Thoreau E, Arlabosse JM, Bouix -Peter C, Chambon S, Chantalat L, Daver S, et al. Structure -based design of Trifarotene (CD5789), a potent and selective RARgamma agonist for the treatment of acne. Bioorg Med Chem Lett . 2018;28(10):1736-41. 12.Del Rosso JQ. The role of skin care as an integral component in the management of acne vulgaris: Part 1: The importance of cleanser and moisturizer ingredients, design, andproduct selection. J Clin Aesthet Dermatol. 2013;6(12):19-27. 13.Davis EC, Callender VD. A review of acne in ethnic skin: pathogenesis, clinicalmanifestations, and management strategies. Jour Clin Aesthet Dermatol ., 2010 Apr; 3(4):24-38. 14.Schorr ES, Sidou F, Kerrouche N. Adjunctive use of a facial moisturizer SPF 30 containingceramide precursor improves tolerabilit y of topical tretinoin 0.05%: a randomized, investigator -blinded, split- face study. J Drugs Dermatol . 2012;11(9):1104-1107. 15.Bowe WP, Kircik LH. Importance of photoprotection and moisturization in treating acnevulgaris . J Drugs Dermatol . 2014 Aug;13(8): s89-94. 16.Del Rosso JQ, Brandt S. The role of skin care as an integral component in the managementof acne vulgaris. Part 2: Tolerability and performance of a designated skin care regimenusing a foam wash and moisturizer SPF 30 in patients with acne vulgaris undergoing active treatment. J Clin Aesthet Dermatol. 2013;6(12):28-36. 17.Usatine R, Quan M, Strick R. Acne vulgaris:a treatment update. Hosp Prac 1998;Feb 15:111-127. 18. Pawin H., Beylot C., Chivot M. et al., Physiopathology of acne vulgaris: recent data, new understanding of the treatments. Eur J Dermatol. 2004 Jan Feb;14(1):4 12."
70,page_70,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 71 of 88 19. Leyden J.J. Topical treatment of acne vulgaris: Retinoids and cutaneous irritation. J Am Acad Dermatol. 1998 Apr; 38(4):S1 4. 20. Rizer, RL, Mills, OH, Trookman, NS. The assessment of acne: a re -evaluation of grading strategies. Scientific Poster, Annual Meeting of the American Academy of Dermatology (2001). 21. Dreno B, Bissonnette R, Gagne -Henley A, et al. Prevention and Reduction of Atrophic Acne Scars with Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel in Subjects with Moderate or Severe Facial Acne: Results of a 6 -Month Randomized, Vehicle -Controlled Trial Using Intra -Individual Comparison. Am J Clin Dermatol. 2018;19(2):275-286. 22. Cook CH, Centner RC, Michaels SE. An acne grading method using photographic standards. Arch Dermatol . 1979;115:571-575."
71,page_71,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
72,page_72,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
73,page_73,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
74,page_74,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 75 of 88 13.3 Dermatology Life Quality Index (DLQI ) The aim of this questionnaire is to measure how much your skin problem has affected your life OVER THE LAST WEEK. Please tick one box for e ach question. 1. Over the last week, how itchy, sore, Very much  painful or stinging has your skin A lot  been? A little  Not at all  2. Over the last week, how embarrassed Very much  or self-conscious have you been because A lot  of your skin? A little  Not at all  3. Over the last week, how much has your Very much  skin interfered with you going A lot  shopping or looking after your home or A little  garden? Not at all  Not relevant  4. Over the last week, how much has your Very much  skin influenced the clothes A lot  you wear? A little  Not at all  Not relevant  5. Over the last week, how much has your Very much  skin affected any social or A lot  leisure activities? A little  Not at all  Not relevant  6. Over the last week, how much has your Very much  skin made it difficult for A lot  you to do any sport ? A little  Not at all  Not relevant  7. Over the last week, has your skin prevented Yes  you from working or studying ? No  Not relevant  If “No”, over the last week how much has A lot  your skin been a problem at A little  work or studying ? Not at all  8. Over the last week, how much has your Very much  skin created problems with your A lot  partner or an y of your close friends A little  or relatives ? Not at all  Not r elevant "
75,page_75,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 76 of 88 9. Over the last week, how much has your Very much  skin caused any sexual difficulties ? A lot  A little  Not at all  Not relevant  10. Over the last week, how much of a Very much  problem has the treatment for your A lot  skin been, for example by making A little  your home messy, or by taking up time? Not at all  Not relevant  Please check that you have answered EVERY question. Thank you. AY Finlay, GK Khan, April 1992, This must not be copied without the permission of the authors."
76,page_76,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 77 of 88 13.4 Children’s Dermatology Life Quality Index (C -DLQI) The aim of this questionnaire is to measure how much your skin problem has affected you OVER THE LAST WEEK. Please tick one box for each question. 1. Over the last week, how itchy , “scratchy” , Very much  sore or painful has your skin been? Quite a lot  Only a little  Not at all  2. Over the last week, how embarrassed Very much  or self conscious , upset or sad have you Quite a lot  been because of your skin? Only a little  Not at all  3. Over the last week, how much has your Very much  skin affected your friendships ? Quite a lot  Only a little  Not at all  4. Over the last week, how much have you changed Very much  or worn different or special clothes/shoes Quite a lot  because of your skin? Only a little  Not at all  5. Over the last week, how much has your Very much  skin trouble affected going out , playing , Quite a lot  or doing hobbies? Only a little  Not at all  6. Over the last week, how much have you Very much  avoided swimming or other sports because Quite a lot  of your skin trouble? Only a little  Not at all  7. Last week , If school time : Over the Prevented school  was it last w eek, how much did Very much  school time? your skin affect your Quite a lot  school work ? Only a little  OR Not at all  was it If holiday time : How much Very much  holiday time? over the last week, has your Quite a lo t  skin problem interfered with Only a little  your enjoyment of the holiday ? Not at all  8. Over the last week, how much trouble Very much  have you had because of your skin with Quite a lot  other people calling you names, teasing , Only a little  bullying , asking questions or avoiding you ? Not at all "
77,page_77,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 78 of 88 9. Over the last week, how much has your sleep Very much  been affected by your skin problem? Quite a lot  Only a little  Not at all  10. Over the last week, how much of a Very much  problem has the treatment for your Quite a lot  skin been? Only a little  Not at all  Please check that you have answered EVERY question. Thank you. M.S. Lewis -Jones, A.Y. Finlay, May 1993, This must not be copied without the permission of the authors."
78,page_78,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 79 of 88 13.5 QOL Q uestionnaire for Face and Trunk Acne (16 years of age and older) Comp AQ Measure (Long Form) We define acne as pimples, zits, or breakouts. We do not mean holes, dark spots, or red spots left by acne. Thinking about the last 7 days , please answer the following questions about acne on your [face/ torso ( eg, chest, back, shoulders)] using the following scale: 0 1 2 3 4 5 6 7 8 Never Rarely Sometimes Often All the time Items, split by domain Response Choices 0 1 2 3 4 5 6 7 8 A.Psychological/Emotional Because of my acne…. 1.I feel depressed, sad, or upset. 2.I feel embarrassed. 3.I feel self -conscious. 4.I feel less confident. B.Social (Judgment from others) Because of my acne… 5.I feel that people stare at me. 6.I feel like people judge me. 7.People treat me differently. 8.People think less of me. C.Social Interactions Because of my acne… 9.I avoid social interactions. 10.I spend less time with my friends. 11.I am concerned about meeting new people. 12.I am uncomfortable showing affection to others. D.Treatment Concerns Because of my acne… 13.I spend a lot time taking care of my skin (at home remedies, treatments, cleansing). 14.I spend time looking at my skin. 15.I am concerned that my skin will never be clear. 16.I am concerned about side effects from treatment. E.Physical Symptoms Because of my acne…"
79,page_79,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 80 of 88 17. My skin feels bumpy or uneven. 18. My skin feels dirty. 19. My skin is red. 20. My skin causes me discomfort or pain. Since your baseline visit in this study, has there been any change in overall quality of life related to your acne? RESPONSE RANGE : Patient instructions: Please circle the number that best describes your response where -7 indicates a great deal WORSE and +7 indicates a great deal BETTER -7 (a great deal WORSE) -6 -5 -4 -3 -2 -1 0 (No change) +1 +2 +3 +4 +5 +6 +7 (a great deal BETTER) The above is based on this section of the paper for MCID determination for DLQI GRCQ The GRCQ [ 4], used as an anchor, allows patients to give a self -assessment of the change since baseline assessment in, for example, overall QoL or severity of skin condition, whether it has improved, remained the same or deteriorated. It has a 15-point scoring system with responses ranging from a very great deal better (+7) to no change (0) to a very great deal worse ( -7). The GRCQ with a 15 -point scoring system was chosen to maximize the sensitivity of the responses. Respondents with scores of 0, -1 or 1 are classified as unchanged or having a small but unimportant change. Respondents whose scores are 2, 3, -2 or -3 are considered to have experienced a small change equivalent to the minimal important difference. Those with scores of 4, 5, -4 or -5 are considered to have experienced a moderate change, and those with scores of 6, 7, -6 or -7 are considered to have experienced a large change [ 3,4]. The question posed was: ‘Since your first clinic visit, has there been any change in overall quality of life related to your skin disease?' REF: Basra M, K, A, Salek M, S, Camilleri L, Sturkey R, Finlay A, Y: D etermining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data. Dermatology 2015;230:27-33. doi: 10.1159/000365390"
80,page_80,GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 81 of 88 13.6 EuroQ oL 5- Dimension ( EQ-5D-5L )
81,page_81,GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 82 of 88
82,page_82,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 83 of 88 13.7 Fitzp atrick Skin Classification The Fitzpatrick skin classification is based on the skin’s unprotected response to the first 30 to 45 minutes of sun exposure after a winter season without sun exposure. The categories of skin types are as follows: I White; very fair; red or blonde hair; blue eyes; freckles Always burns easily; never tans II White; fair; red or blonde hair; blue, hazel, or green eyes Always burns easily; tans minimally III Cream white; fair with any eye or hair color; very common Burns moderately; tans gradually IV Brown; typical Mediterranean white skin Burns minimally; always tans well V Dark brown; mid- eastern skin types, black hair, olive skin Rarely burns; tans profusely VI Black; black hair, black eyes, black skin Never burns; deeply pigmented"
83,page_83,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
84,page_84,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
85,page_85,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
86,page_86,*$/'(50$5 ' 5'635 3URWRFRO9-XQ  3DJHRI CCI
87,page_87,"GALDERMA R&D RD.06.SPR.118295 Protocol V02 04Jun2019 Page 88 of 88 Protoc ol Signature Page I agree to conduct the trial in compliance: •With the protocol, or any applicable amendment(s), agreed to by the sponsor, regulatory authority and which was given a favorable opinion by the IRB/IEC •With Good Clinical Practices •With applicable local and international laws and regulations •With the instructions I received about −ethic principles and subjects protection −data collection and reporting −study drug(s) and material(s) use and management −clinical trial monitoring, audit and inspection I have read this protocol in its entirety, including the above statement, and I agree to all aspects. Investigator (first name/last name) Signature Date:"
